

(12) **United States Patent**  
**Barthe et al.**

(10) **Patent No.:** **US 9,427,600 B2**  
(45) **Date of Patent:** **\*Aug. 30, 2016**

(54) **SYSTEMS FOR TREATING SKIN LAXITY**

(71) Applicant: **Guided Therapy Systems, L.L.C.**,  
Mesa, AZ (US)

(72) Inventors: **Peter G. Barthe**, Phoenix, AZ (US);  
**Michael H. Slayton**, Tempe, AZ (US);  
**Inder Raj S. Makin**, Mesa, AZ (US)

(73) Assignee: **Guided Therapy Systems, L.L.C.**,  
Mesa, AZ (US)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.  
  
This patent is subject to a terminal dis-  
claimer.

(21) Appl. No.: **14/692,114**

(22) Filed: **Apr. 21, 2015**

(65) **Prior Publication Data**

US 2015/0224347 A1 Aug. 13, 2015

**Related U.S. Application Data**

(63) Continuation of application No. 14/169,709, filed on  
Jan. 31, 2014, now Pat. No. 9,039,619, which is a  
continuation of application No. 13/230,498, filed on  
Sep. 12, 2011, now Pat. No. 8,641,622, which is a

(Continued)

(51) **Int. Cl.**

**A61B 8/00** (2006.01)

**A61N 7/00** (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC ..... **A61N 7/00** (2013.01); **A61B 5/682**  
(2013.01); **A61B 5/6842** (2013.01); **A61B 8/08**  
(2013.01); **A61B 8/0858** (2013.01); **A61B 8/12**  
(2013.01);

(Continued)

(58) **Field of Classification Search**

CPC ..... **A61N 7/02**; **A61N 2007/0008**  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

2,427,348 A 9/1947 Bond et al.

3,913,386 A 10/1975 Saglio

(Continued)

**FOREIGN PATENT DOCUMENTS**

CN 104027893 9/2014

DE 4029175 3/1992

(Continued)

**OTHER PUBLICATIONS**

Alster, Tinas S., Tanzi, Elizabeth L., "Cellulite Treatment using a  
Novel Combination Radiofrequency, Infrared Light, and Mechan-  
ical Tissue Manipulation Device," Journal of Cosmetic & Laser  
Therapy, Jun. 2005, vol. 7, Issue 2, pp. 81-85.

(Continued)


*Primary Examiner* — Bo J Peng

(74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson &  
Bear, LLP

(57) **ABSTRACT**

A system and method for ultrasound treatment of skin laxity  
are provided. Systems and methods can include ultrasound  
imaging of the region of interest for localization of the  
treatment area, delivering ultrasound energy at a depth and  
pattern to achieve the desired therapeutic effects, and/or  
monitoring the treatment area to assess the results and/or  
provide feedback. In an embodiment, a treatment system and  
method can be configured for producing arrays of sub-  
millimeter and larger zones of thermal ablation to treat the  
epidermal, superficial dermal, mid-dermal and deep dermal  
components of tissue.

**20 Claims, 22 Drawing Sheets**



Related U.S. Application Data					
continuation of application No. 11/163,150, filed on Oct. 6, 2005, now Pat. No. 8,066,641.			4,757,820	A	7/1988 Itoh
			4,771,205	A	9/1988 Mequio
			4,801,459	A	1/1989 Liburdy
			4,803,625	A	2/1989 Fu et al.
			4,807,633	A	2/1989 Fry
(60) Provisional application No. 60/617,295, filed on Oct. 7, 2004.			4,817,615	A	4/1989 Fukukita et al.
			4,858,613	A	8/1989 Fry
			4,860,732	A	8/1989 Hasegawa et al.
(51) Int. Cl.			4,865,041	A	9/1989 Hassler
<i>A61B 5/00</i>	(2006.01)		4,865,042	A	9/1989 Umemura
<i>A61B 8/08</i>	(2006.01)		4,867,169	A	9/1989 Machida
<i>A61B 8/12</i>	(2006.01)		4,874,562	A	10/1989 Hyon
<i>A61H 23/02</i>	(2006.01)		4,875,487	A	10/1989 Seppi
<i>A61N 7/02</i>	(2006.01)		4,881,212	A	11/1989 Takeuchi
<i>G01S 15/89</i>	(2006.01)		4,891,043	A	1/1990 Zeimer et al.
<i>A61B 8/13</i>	(2006.01)		4,893,624	A	1/1990 Lele
<i>A61B 17/32</i>	(2006.01)		4,896,673	A	1/1990 Rose
(52) U.S. Cl.			4,900,540	A	2/1990 Ryan et al.
CPC .....	<i>A61B 8/13</i> (2013.01); <i>A61B 8/4483</i>		4,901,729	A	2/1990 Saitoh
	(2013.01); <i>A61B 8/483</i> (2013.01); <i>A61B 8/546</i>		4,917,096	A	4/1990 Englehart
	(2013.01); <i>A61B 17/320068</i> (2013.01); <i>A61H</i>		4,973,096	A	4/1990 Jaworski
	<i>23/0245</i> (2013.01); <i>A61N 7/02</i> (2013.01);		4,932,414	A *	6/1990 Coleman ..... A61B 8/14
	<i>G01S 15/8909</i> (2013.01); <i>A61B 8/4209</i>				128/916
	(2013.01); <i>A61B 8/4281</i> (2013.01); <i>A61B</i>		4,938,216	A	7/1990 Lele
	<i>8/4455</i> (2013.01); <i>A61H 2201/5007</i> (2013.01);		4,938,217	A	7/1990 Lele
	<i>A61N 2007/0008</i> (2013.01); <i>A61N 2007/0034</i>		4,947,046	A	8/1990 Kawabata et al.
	(2013.01)		4,951,653	A	8/1990 Fry
			4,955,365	A	9/1990 Fry
			4,958,626	A	9/1990 Nambu
			4,976,709	A	12/1990 Sand
			4,979,501	A	12/1990 Valchanov
			4,992,989	A	2/1991 Watanabe et al.
			5,012,797	A	5/1991 Liang
(56) References Cited			5,018,508	A *	5/1991 Fry ..... A61N 7/00
U.S. PATENT DOCUMENTS					601/2
3,965,455	A	6/1976 Hurwitz	5,030,874	A	7/1991 Saito et al.
3,992,925	A	11/1976 Perilhou	5,036,855	A	8/1991 Fry
4,039,312	A	8/1977 Patru	5,040,537	A	8/1991 Katakura
4,059,098	A	11/1977 Murdock	5,054,310	A	10/1991 Flynn
4,101,795	A	7/1978 Fukumoto	5,054,470	A	10/1991 Fry
4,166,967	A	9/1979 Benes et al.	5,070,879	A	12/1991 Herres
4,211,948	A	7/1980 Smith et al.	5,088,495	A	2/1992 Miyagawa
4,211,949	A	7/1980 Brisken et al.	5,115,814	A	5/1992 Griffith
4,213,344	A	7/1980 Rose	5,117,832	A	6/1992 Sanghvi
4,276,491	A	6/1981 Daniel	5,123,418	A	6/1992 Saurel
4,315,514	A	2/1982 Drewes et al.	5,143,063	A	9/1992 Fellner
4,325,381	A	4/1982 Glenn	5,143,074	A	9/1992 Dory
4,343,301	A	8/1982 Indech	5,149,319	A	9/1992 Unger
4,372,296	A	2/1983 Fahim	5,150,711	A	9/1992 Dory
4,379,145	A	4/1983 Masuho et al.	5,150,714	A	9/1992 Green
4,381,007	A	4/1983 Doss	5,152,294	A	10/1992 Mochizuki et al.
4,381,787	A	5/1983 Hottinger	5,156,144	A	10/1992 Iwasaki
4,397,314	A	8/1983 Vaguine	5,158,536	A	10/1992 Sekins
4,409,839	A	10/1983 Taenzer	5,159,931	A	11/1992 Pini
4,431,008	A	2/1984 Wanner et al.	5,163,421	A	11/1992 Bernstein
4,441,486	A	4/1984 Pounds	5,163,436	A	11/1992 Saitoh et al.
4,452,084	A	6/1984 Taenzer	5,178,135	A	1/1993 Uchiyama et al.
4,484,569	A	11/1984 Driller	5,190,518	A	3/1993 Takasu
4,507,582	A	3/1985 Glenn	5,190,766	A	3/1993 Ishihara
4,513,749	A	4/1985 Kino	5,191,880	A	3/1993 McLeod
4,513,750	A	4/1985 Heyman et al.	5,205,287	A	4/1993 Erbel et al.
4,527,550	A	7/1985 Ruggera et al.	5,209,720	A	5/1993 Unger
4,528,979	A	7/1985 Marchenko	5,212,671	A	5/1993 Fujii et al.
4,534,221	A	8/1985 Fife et al.	5,215,680	A	6/1993 D'Arrigo
4,566,459	A	1/1986 Umemura et al.	5,224,467	A	7/1993 Oku
4,567,895	A	2/1986 Putzke	5,230,334	A	7/1993 Klopotek
4,586,512	A	5/1986 Do-Huu	5,230,338	A	7/1993 Allen et al.
4,601,296	A	7/1986 Yerushalmi	5,247,924	A	9/1993 Suzuki et al.
4,620,546	A	11/1986 Aida et al.	5,255,681	A	10/1993 Ishimura et al.
4,637,256	A	1/1987 Sugiyama et al.	5,257,970	A	11/1993 Dougherty
4,646,756	A	3/1987 Watmough	5,265,614	A	11/1993 Hayakawa
4,663,358	A	5/1987 Hyon	5,267,985	A	12/1993 Shimada
4,668,516	A	5/1987 Duraffourd et al.	5,269,297	A	12/1993 Weng
4,672,591	A	6/1987 Breimesser et al.	5,282,797	A	2/1994 Chess
4,680,499	A	7/1987 Umemura et al.	5,295,484	A	3/1994 Marcus
4,697,588	A	10/1987 Reichenberger	5,295,486	A	3/1994 Wollschlager et al.
4,754,760	A	7/1988 Fukukita et al.	5,304,169	A	4/1994 Sand
			5,305,756	A	4/1994 Entrekina et al.
			5,321,520	A	6/1994 Inga et al.

(56)	<b>References Cited</b>		5,658,328 A	8/1997	Johnson	
	U.S. PATENT DOCUMENTS		5,660,836 A *	8/1997	Knowlton	A61B 18/12 128/898
	5,323,779 A	6/1994 Hardy et al.	5,662,116 A	9/1997	Kondo	
	5,327,895 A	7/1994 Hashimoto et al.	5,665,053 A	9/1997	Jacobs	
	5,348,016 A	9/1994 Unger et al.	5,665,141 A	9/1997	Vago	
	5,360,268 A	11/1994 Hayashi	5,671,746 A	9/1997	Dreschel et al.	
	5,370,121 A	12/1994 Reichenberger	5,673,699 A	10/1997	Trahey et al.	
	5,371,483 A	12/1994 Bhardwaj	5,676,692 A	10/1997	Sanghvi	
	5,375,602 A	12/1994 Lancee et al.	5,685,820 A	11/1997	Riek et al.	
	5,379,773 A	1/1995 Hornsby	5,690,608 A	11/1997	Watanabe	
	5,380,280 A	1/1995 Peterson	5,694,936 A	12/1997	Fujimoto	
	5,380,519 A	1/1995 Schneider et al.	5,697,897 A	12/1997	Buchholtz	
	5,383,917 A	1/1995 Desai et al.	5,701,900 A	12/1997	Shehada et al.	
	5,391,140 A	2/1995 Schaetzle et al.	5,704,361 A	1/1998	Seward et al.	
	5,391,197 A	2/1995 Burdette et al.	5,706,252 A	1/1998	Le Verrier et al.	
	5,392,259 A	2/1995 Bolorforosh	5,706,564 A	1/1998	Rhyne	
	5,396,143 A	3/1995 Seyed-Bolorforosh et al.	5,715,823 A	2/1998	Wood et al.	
	5,398,689 A	3/1995 Connor et al.	5,720,287 A	2/1998	Chapelon et al.	
	5,406,503 A	4/1995 Williams	5,722,411 A	3/1998	Suzuki	
	5,413,550 A *	5/1995 Castel ..... A61H 23/0245 601/2	5,727,554 A	3/1998	Kalend et al.	
	5,417,216 A	5/1995 Tanaka	5,735,280 A	4/1998	Sherman et al.	
	5,419,327 A	5/1995 Rohwedder	5,743,863 A	4/1998	Chapelon	
	5,423,220 A	6/1995 Finsterwald et al.	5,746,005 A	5/1998	Steinberg	
	5,435,311 A	7/1995 Umemura	5,746,762 A	5/1998	Bass	
	5,438,998 A	8/1995 Hanafy	5,748,767 A	5/1998	Raab	
	5,443,068 A *	8/1995 Cline ..... A61B 5/0555 600/411	5,749,364 A	5/1998	Sliwa et al.	
	5,458,596 A	10/1995 Lax	5,755,228 A	5/1998	Wilson et al.	
	5,460,179 A	10/1995 Okunuki et al.	5,755,753 A	5/1998	Knowlton	
	5,460,595 A	10/1995 Hall et al.	5,762,066 A	6/1998	Law	
	5,469,854 A	11/1995 Unger et al.	5,763,886 A	6/1998	Schulte	
	5,471,988 A	12/1995 Fujio	5,769,790 A	6/1998	Watkins	
	5,487,388 A	1/1996 Rello et al.	5,779,644 A	7/1998	Eberle et al.	
	5,492,126 A	2/1996 Hennige	5,792,058 A	8/1998	Lee	
	5,496,256 A	3/1996 Bock	5,795,297 A	8/1998	Daigle	
	5,501,655 A	3/1996 Rolt	5,795,311 A	8/1998	Wess	
	5,503,152 A	4/1996 Oakley et al.	5,810,009 A	9/1998	Mine et al.	
	5,503,320 A	4/1996 Webster et al.	5,810,888 A	9/1998	Fenn	
	5,507,790 A	4/1996 Weiss	5,814,599 A	9/1998	Mitragotri et al.	
	5,511,296 A	4/1996 Dias et al.	5,817,013 A	10/1998	Ginn et al.	
	5,520,188 A	5/1996 Hennige	5,817,021 A	10/1998	Reichenberger	
	5,522,869 A	6/1996 Burdette	5,820,564 A	10/1998	Slayton	
	5,523,058 A	6/1996 Umemura et al.	5,823,962 A	10/1998	Schaetzle	
	5,524,620 A	6/1996 Rosencheim	5,827,204 A	10/1998	Grandia et al.	
	5,524,624 A	6/1996 Tepper	5,840,032 A	11/1998	Hatfield et al.	
	5,524,625 A	6/1996 Okazaki	5,844,140 A	12/1998	Seale	
	5,526,624 A	6/1996 Berg	5,853,367 A	12/1998	Chalek et al.	
	5,526,812 A	6/1996 Dumoulin et al.	5,869,751 A	2/1999	Bonin	
	5,526,814 A	6/1996 Cline et al.	5,871,524 A	2/1999	Knowlton	
	5,526,815 A	6/1996 Granz	5,873,902 A	2/1999	Sanghvi	
	5,529,070 A	6/1996 Augustine et al.	5,876,341 A	3/1999	Wang et al.	
	5,540,235 A	7/1996 Wilson	5,879,303 A	3/1999	Averkio et al.	
	5,558,092 A	9/1996 Unger	5,882,557 A	3/1999	Hayakawa	
	5,560,362 A	10/1996 Sliwa et al.	5,891,034 A	4/1999	Buchholz	
	5,575,291 A	11/1996 Hayakawa	5,895,356 A	4/1999	Andrus et al.	
	5,575,807 A	11/1996 Faller	5,899,861 A	5/1999	Friemel et al.	
	5,577,502 A	11/1996 Darrow et al.	5,904,659 A	5/1999	Duarte	
	5,577,507 A	11/1996 Snyder et al.	5,919,219 A	7/1999	Knowlton	
	5,577,991 A	11/1996 Akui et al.	5,923,099 A	7/1999	Bilir	
	5,580,575 A	12/1996 Unger et al.	5,924,989 A	7/1999	Polz	
	5,601,526 A *	2/1997 Chapelon ..... A61N 7/02 601/2	5,928,169 A	7/1999	Schatzle et al.	
	5,603,323 A	2/1997 Pflugrath et al.	5,931,805 A	8/1999	Briskin	
	5,609,562 A	3/1997 Kaali	5,938,606 A	8/1999	Bonnefous	
	5,615,091 A	3/1997 Palatnik	5,938,612 A	8/1999	Kline-Schoder	
	5,617,858 A	4/1997 Taverna et al.	5,948,011 A	9/1999	Knowlton	
	5,618,275 A	4/1997 Bock	5,957,844 A	9/1999	Dekel	
	5,620,479 A	4/1997 Diederich	5,957,882 A	9/1999	Nita et al.	
	5,622,175 A	4/1997 Sudol et al.	5,957,941 A	9/1999	Ream	
	5,638,819 A	6/1997 Manwaring et al.	5,964,707 A	10/1999	Fenster et al.	
	5,643,179 A	7/1997 Fujimoto	5,967,980 A	10/1999	Ferre et al.	
	5,644,085 A	7/1997 Lorraine et al.	5,968,034 A	10/1999	Fullmer	
	5,647,373 A	7/1997 Paltiel	5,971,949 A	10/1999	Levin	
	5,655,535 A	8/1997 Friemel et al.	5,977,538 A	11/1999	Unger et al.	
	5,655,538 A	8/1997 Lorraine	5,984,881 A	11/1999	Ishibashi et al.	
	5,657,760 A	8/1997 Ying	5,984,882 A	11/1999	Rosenschein	
			5,990,598 A	11/1999	Sudol et al.	
			5,997,471 A	12/1999	Gumb et al.	
			5,997,497 A	12/1999	Nita et al.	
			5,999,843 A	12/1999	Anbar	

(56)

## References Cited

## U.S. PATENT DOCUMENTS

6,004,262	A	12/1999	Putz et al.	6,375,672	B1	4/2002	Aksan
6,007,499	A	12/1999	Martin et al.	6,377,854	B1	4/2002	Knowlton
6,013,032	A	1/2000	Savord	6,377,855	B1	4/2002	Knowlton
6,016,255	A	1/2000	Bolan et al.	6,381,497	B1	4/2002	Knowlton
6,019,724	A	2/2000	Gronningsaeter et al.	6,381,498	B1	4/2002	Knowlton
6,022,308	A	2/2000	Williams	6,387,380	B1	5/2002	Knowlton
6,022,327	A	2/2000	Chang	6,390,982	B1	5/2002	Bova et al.
6,030,374	A	2/2000	McDaniel	6,405,090	B1	6/2002	Knowlton
6,036,646	A	3/2000	Barthe	6,409,720	B1	6/2002	Hissong
6,039,048	A	3/2000	Silberg	6,413,216	B1	7/2002	Cain et al.
6,039,689	A	3/2000	Lizzi	6,413,253	B1	7/2002	Koop
6,042,556	A	3/2000	Beach	6,413,254	B1	7/2002	Hissong
6,049,159	A	4/2000	Barthe	6,419,648	B1	7/2002	Vitek
6,050,943	A	4/2000	Slayton	6,423,007	B2	7/2002	Lizzi et al.
6,059,727	A	5/2000	Fowlkes	6,425,865	B1	7/2002	Salcudean
6,071,239	A	6/2000	Cribbs	6,425,867	B1	7/2002	Vaezy
6,080,108	A	6/2000	Dunham	6,425,912	B1	7/2002	Knowlton
6,083,148	A	7/2000	Williams	6,428,477	B1	8/2002	Mason
6,086,535	A	7/2000	Ishibashi	6,428,532	B1	8/2002	Doukas
6,086,580	A	7/2000	Mordon et al.	6,430,446	B1	8/2002	Knowlton
6,090,054	A	7/2000	Tagishi	6,432,057	B1	8/2002	Mazess et al.
6,093,148	A *	7/2000	Fujimoto	6,432,067	B1	8/2002	Martin
			..... A61N 7/00	6,432,101	B1	8/2002	Weber
			600/438	6,436,061	B1	8/2002	Costantino
6,093,883	A	7/2000	Sanghvi	6,438,424	B1	8/2002	Knowlton
6,101,407	A	8/2000	Groezienger	6,440,071	B1	8/2002	Slayton
6,106,469	A	8/2000	Suzuki et al.	6,440,121	B1	8/2002	Weber
6,113,558	A	9/2000	Rosenchein	6,443,914	B1 *	9/2002	Costantino
6,113,559	A	9/2000	Klopotek				..... A61M 25/0026
6,120,452	A	9/2000	Barthe	6,447,443	B1	9/2002	Keogh et al.
6,123,081	A	9/2000	Durette	6,451,013	B1	9/2002	Bays et al.
6,126,619	A	10/2000	Peterson et al.	6,453,202	B1	9/2002	Knowlton
6,135,971	A	10/2000	Hutchinson	6,461,378	B1	10/2002	Knowlton
6,139,499	A	10/2000	Wilk	6,470,216	B1	10/2002	Knowlton
6,159,150	A	12/2000	Yale et al.	6,488,626	B1	12/2002	Lizzi
6,171,244	B1	1/2001	Finger et al.	6,491,657	B2	12/2002	Rowe
6,176,840	B1	1/2001	Nishimura	6,500,121	B1	12/2002	Slayton
6,183,426	B1	2/2001	Akisada	6,500,141	B1	12/2002	Irion
6,183,502	B1	2/2001	Takeuchi	6,506,171	B1	1/2003	Vitek et al.
6,183,773	B1	2/2001	Anderson	6,508,774	B1	1/2003	Acker
6,190,323	B1	2/2001	Dias	6,511,427	B1	1/2003	Sliwa, Jr. et al.
6,190,336	B1	2/2001	Duarte	6,511,428	B1 *	1/2003	Azuma
6,193,658	B1	2/2001	Wendelken				..... A61N 7/022
6,210,327	B1	4/2001	Brackett et al.	6,514,244	B2	2/2003	Pope
6,213,948	B1	4/2001	Barthe	6,517,484	B1	2/2003	Wilk
6,216,029	B1	4/2001	Paltieli	6,524,250	B1	2/2003	Weber
6,233,476	B1	5/2001	Strommer et al.	6,540,679	B2	4/2003	Slayton
6,234,990	B1	5/2001	Rowe et al.	6,540,685	B1	4/2003	Rhoads et al.
6,241,753	B1 *	6/2001	Knowlton	6,540,700	B1	4/2003	Fujimoto et al.
			..... A61B 18/12	6,547,788	B1	4/2003	Maguire et al.
			128/898	6,554,771	B1	4/2003	Buil et al.
6,246,898	B1	6/2001	Vesely et al.	6,569,099	B1	5/2003	Babaev
6,251,074	B1	6/2001	Averkio et al.	6,569,108	B2	5/2003	Sarvazy et al.
6,251,088	B1	6/2001	Kaufman et al.	6,572,552	B2	6/2003	Fukukita
6,268,405	B1	7/2001	Yao	6,575,956	B1	6/2003	Briskin et al.
6,273,864	B1	8/2001	Duarte	6,595,934	B1 *	7/2003	Hissong
6,280,402	B1	8/2001	Ishibashi et al.				..... A61N 7/02
6,287,257	B1	9/2001	Matichuk	6,599,256	B1	7/2003	Acker
6,287,304	B1	9/2001	Eggers et al.	6,605,080	B1	8/2003	Altshuler et al.
6,296,619	B1	10/2001	Briskin	6,607,498	B2	8/2003	Eshel
6,301,989	B1	10/2001	Brown et al.	6,618,620	B1	9/2003	Freundlich et al.
6,307,302	B1	10/2001	Toda	6,623,430	B1	9/2003	Slayton
6,309,355	B1	10/2001	Cain et al.	6,626,854	B2	9/2003	Friedman
6,311,090	B1	10/2001	Knowlton	6,626,855	B1	9/2003	Weng
6,315,741	B1 *	11/2001	Martin	6,638,226	B2	10/2003	He et al.
			..... A61B 8/4461	6,645,150	B2	11/2003	Angelsen et al.
			601/3	6,645,162	B2	11/2003	Friedman
6,322,509	B1	11/2001	Pan et al.	6,662,054	B2	12/2003	Kreindel
6,322,532	B1	11/2001	D'Sa	6,663,627	B2	12/2003	Francischelli
6,325,540	B1	12/2001	Lounsbury et al.	6,665,806	B1	12/2003	Shimizu
6,325,758	B1	12/2001	Carol et al.	6,666,835	B2	12/2003	Martin
6,325,769	B1	12/2001	Klopotek	6,669,638	B1	12/2003	Miller
6,325,798	B1	12/2001	Edwards et al.	6,685,640	B1	2/2004	Fry
6,338,716	B1	1/2002	Hossack et al.	6,692,450	B1	2/2004	Coleman
6,350,276	B1	2/2002	Knowlton	6,699,237	B2	3/2004	Weber
6,356,780	B1	3/2002	Licato et al.	6,716,184	B2	4/2004	Vaezy et al.
6,361,531	B1	3/2002	Hissong	6,719,449	B1	4/2004	Laughlin
6,370,411	B1	4/2002	Osadchy et al.	6,719,694	B2	4/2004	Weng
				6,726,627	B1	4/2004	Lizzi et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

6,733,449 B1	5/2004	Krishnamurthy et al.	7,652,411 B2	1/2010	Crunkilton et al.
6,749,624 B2	6/2004	Knowlton	7,662,114 B2	2/2010	Seip et al.
6,772,490 B2	8/2004	Toda	7,674,257 B2	3/2010	Pless et al.
6,773,409 B2	8/2004	Truckai et al.	7,686,763 B2	3/2010	Vaezy et al.
6,775,404 B1	8/2004	Pagoulatos et al.	7,694,406 B2	4/2010	Wildes et al.
6,790,187 B2	9/2004	Thompson et al.	7,695,437 B2	4/2010	Quistgaard et al.
6,824,516 B2	11/2004	Batten et al.	7,713,203 B2	5/2010	Lacoste et al.
6,835,940 B2	12/2004	Morikawa et al.	7,727,156 B2	6/2010	Angelsen et al.
6,846,290 B2	1/2005	Lizzi et al.	7,758,524 B2	7/2010	Barthe
6,875,176 B2	4/2005	Mourad	7,766,848 B2	8/2010	Desilets et al.
6,882,884 B1	4/2005	Mosk et al.	7,789,841 B2	9/2010	Huckle et al.
6,887,239 B2	5/2005	Elstrom	7,806,839 B2	10/2010	Mast et al.
6,889,089 B2	5/2005	Behl	7,815,570 B2	10/2010	Eshel et al.
6,896,657 B2	5/2005	Willis	7,819,826 B2	10/2010	Diederich et al.
6,902,536 B2	6/2005	Manna	7,824,348 B2	11/2010	Barthe
6,905,466 B2	6/2005	Salgo	7,828,734 B2	11/2010	Azhari et al.
6,918,907 B2	7/2005	Kelly	7,833,162 B2	11/2010	Hasegawa et al.
6,920,883 B2	7/2005	Bessette	7,841,984 B2	11/2010	Cribbs et al.
6,921,371 B2	7/2005	Wilson	7,846,096 B2	12/2010	Mast et al.
6,932,771 B2	8/2005	Whitmore	7,857,773 B2	12/2010	Desilets et al.
6,932,814 B2	8/2005	Wood	7,875,023 B2	1/2011	Eshel et al.
6,936,044 B2	8/2005	McDaniel	7,901,359 B2	3/2011	Mandrusov et al.
6,936,046 B2	8/2005	Hissong	7,905,007 B2	3/2011	Calisti et al.
6,945,937 B2	9/2005	Culp et al.	7,905,844 B2	3/2011	Desilets et al.
6,948,843 B2	9/2005	Laugharn et al.	7,914,453 B2	3/2011	Slayton et al.
6,953,941 B2	10/2005	Nakano et al.	7,914,469 B2	3/2011	Torbati
6,958,043 B2	10/2005	Hissong	7,931,611 B2	4/2011	Novak et al.
6,971,994 B1	12/2005	Young et al.	7,955,262 B2	6/2011	Rosenberg
6,974,417 B2	12/2005	Lockwood	7,955,281 B2	6/2011	Pedersen et al.
6,976,492 B2	12/2005	Ingle	7,967,764 B2	6/2011	Lidgren et al.
6,992,305 B2	1/2006	Maezawa et al.	7,967,839 B2	6/2011	Flock et al.
6,997,923 B2	2/2006	Anderson	7,993,289 B2	8/2011	Quistgaard et al.
7,006,874 B2	2/2006	Knowlton	8,057,389 B2	11/2011	Barthe et al.
7,020,528 B2	3/2006	Neev	8,057,465 B2	11/2011	Sliwa, Jr. et al.
7,022,089 B2	4/2006	Ooba	8,066,641 B2	11/2011	Barthe et al.
7,058,440 B2	6/2006	Heuscher et al.	8,123,707 B2	2/2012	Huckle et al.
7,063,666 B2	6/2006	Weng	8,128,618 B2	3/2012	Gliklich et al.
7,070,565 B2	7/2006	Vaezy et al.	8,133,180 B2	3/2012	Slayton et al.
7,074,218 B2	7/2006	Washington et al.	8,133,191 B2	3/2012	Rosenberg et al.
7,094,252 B2	8/2006	Koop	8,142,200 B2	3/2012	Crunkilton et al.
7,108,663 B2	9/2006	Talish et al.	8,152,904 B2	4/2012	Slobodzian et al.
7,115,123 B2	10/2006	Knowlton	8,162,858 B2	4/2012	Manna et al.
7,122,029 B2	10/2006	Koop et al.	8,166,332 B2	4/2012	Barthe et al.
7,142,905 B2	11/2006	Slayton	8,182,428 B2	5/2012	Angelsen et al.
7,165,451 B1	1/2007	Brooks et al.	8,197,409 B2	6/2012	Foley et al.
7,179,238 B2	2/2007	Hissong	8,206,299 B2	6/2012	Foley et al.
7,189,230 B2	3/2007	Knowlton	8,208,346 B2	6/2012	Crunkilton
7,229,411 B2	6/2007	Slayton	8,211,017 B2	7/2012	Foley et al.
7,235,592 B2	6/2007	Muratoglu	8,262,591 B2	9/2012	Pedersen et al.
7,258,674 B2	8/2007	Cribbs	8,262,650 B2	9/2012	Zanelli et al.
7,273,459 B2	9/2007	Desilets	8,264,126 B2	9/2012	Toda et al.
7,294,125 B2	11/2007	Phalen et al.	8,273,037 B2	9/2012	Kreindel et al.
7,297,117 B2	11/2007	Trucco	8,282,554 B2	10/2012	Makin et al.
7,303,555 B2	12/2007	Makin et al.	8,292,835 B1	10/2012	Cimino
7,311,679 B2	12/2007	Desilets et al.	8,298,163 B1	10/2012	Cimino
7,327,071 B2	2/2008	Nishiyama et al.	8,333,700 B1	12/2012	Barthe et al.
7,331,951 B2	2/2008	Eshel et al.	8,334,637 B2	12/2012	Crunkilton et al.
7,332,985 B2	2/2008	Larson et al.	8,337,407 B2	12/2012	Quistgaard et al.
7,338,434 B1	3/2008	Haarstad et al.	8,343,051 B2	1/2013	Desilets et al.
7,347,855 B2	3/2008	Eshel	8,366,622 B2	2/2013	Slayton et al.
RE40,403 E	6/2008	Cho et al.	8,388,535 B2	3/2013	Weng et al.
7,393,325 B2	7/2008	Barthe	8,409,097 B2	4/2013	Slayton et al.
7,398,116 B2	7/2008	Edwards	8,425,435 B2	4/2013	Wing et al.
7,399,279 B2	7/2008	Abend et al.	8,444,562 B2	5/2013	Barthe et al.
7,491,171 B2	2/2009	Barthe et al.	8,454,540 B2	6/2013	Eshel et al.
7,507,235 B2	3/2009	Keogh et al.	8,460,193 B2	6/2013	Barthe et al.
7,510,536 B2	3/2009	Foley et al.	8,480,585 B2	7/2013	Slayton et al.
7,517,315 B2	4/2009	Willis	8,506,486 B2	8/2013	Slayton et al.
7,530,356 B2	5/2009	Slayton	8,512,250 B2	8/2013	Quistgaard et al.
7,530,958 B2	5/2009	Slayton	8,523,775 B2	9/2013	Barthe et al.
7,532,201 B2	5/2009	Quistgaard et al.	8,535,228 B2	9/2013	Slayton et al.
7,571,336 B2	8/2009	Barthe	8,570,837 B2	10/2013	Toda et al.
7,601,120 B2	10/2009	Moilanen et al.	8,573,392 B2	11/2013	Bennett et al.
7,615,015 B2	11/2009	Coleman	8,583,211 B2	11/2013	Salomir et al.
7,615,016 B2	11/2009	Barthe	8,585,618 B2	11/2013	Hunziker et al.
			8,604,672 B2	12/2013	Toda et al.
			8,622,937 B2	1/2014	Weng et al.
			8,636,665 B2	1/2014	Slayton et al.
			8,641,622 B2	2/2014	Barthe et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

8,663,112 B2	3/2014	Slayton et al.	2003/0074023 A1	4/2003	Kaplan
8,672,848 B2	3/2014	Slayton et al.	2003/0083536 A1	5/2003	Eshel
8,690,778 B2	4/2014	Slayton et al.	2003/0092988 A1	5/2003	Makin
8,690,779 B2	4/2014	Slayton et al.	2003/0097071 A1	5/2003	Halmann et al.
8,690,780 B2	4/2014	Slayton et al.	2003/0099383 A1	5/2003	Lefebvre
8,708,935 B2	4/2014	Barthe et al.	2003/0125629 A1	7/2003	Ustuner
8,715,186 B2	5/2014	Slayton et al.	2003/0135135 A1	7/2003	Miwa et al.
8,726,781 B2	5/2014	Eckhoff et al.	2003/0139790 A1	7/2003	Ingle et al.
8,728,071 B2	5/2014	Lischinsky et al.	2003/0153961 A1	8/2003	Babaev
8,753,295 B2	6/2014	Thierman	2003/0171678 A1	9/2003	Batten et al.
8,758,253 B2	6/2014	Sano et al.	2003/0171701 A1	9/2003	Babaev
8,836,203 B2	9/2014	Nobles et al.	2003/0176790 A1	9/2003	Slayton
8,857,438 B2	10/2014	Barthe et al.	2003/0191396 A1	10/2003	Sanghvi
8,858,471 B2	10/2014	Barthe et al.	2003/0200481 A1	10/2003	Stanley
8,915,853 B2	12/2014	Barthe et al.	2003/0212129 A1	11/2003	Liu et al.
8,915,854 B2	12/2014	Slayton et al.	2003/0212351 A1	11/2003	Hissong
8,915,870 B2	12/2014	Barthe et al.	2003/0212393 A1	11/2003	Knowlton
8,920,320 B2	12/2014	Stecco et al.	2003/0216648 A1	11/2003	Lizzi et al.
8,920,324 B2	12/2014	Slayton et al.	2003/0216795 A1	11/2003	Harth
8,926,533 B2	1/2015	Bockenstedt et al.	2003/0220536 A1	11/2003	Hissong
8,932,224 B2	1/2015	Barthe et al.	2003/0220585 A1	11/2003	Hissong
8,932,238 B2	1/2015	Wing et al.	2003/0229331 A1	12/2003	Briskin et al.
8,968,205 B2	3/2015	Zeng et al.	2003/0233085 A1	12/2003	Giammarusti
9,011,336 B2	4/2015	Slayton et al.	2003/0236487 A1	12/2003	Knowlton
9,039,619 B2	5/2015	Barthe et al.	2004/0000316 A1	1/2004	Knowlton
9,095,697 B2	8/2015	Barthe et al.	2004/0001809 A1	1/2004	Briskin
2001/0009997 A1	7/2001	Pope	2004/0002705 A1	1/2004	Knowlton
2001/0009999 A1	7/2001	Kaufman et al.	2004/0010222 A1	1/2004	Nunomura et al.
2001/0014780 A1	8/2001	Martin	2004/0015079 A1	1/2004	Berger et al.
2001/0014819 A1	8/2001	Ingle	2004/0015106 A1	1/2004	Coleman
2001/0031922 A1 *	10/2001	Weng ..... A61B 17/0057 600/439	2004/0030227 A1	2/2004	Littrup
2001/0039380 A1	11/2001	Larson et al.	2004/0039312 A1	2/2004	Hillstead
2001/0041880 A1	11/2001	Briskin	2004/0039418 A1	2/2004	Elstrom
2002/0000763 A1	1/2002	Jones	2004/0041563 A1	3/2004	Lewin et al.
2002/0002345 A1	1/2002	Marlinghaus	2004/0041880 A1	3/2004	Ikeda et al.
2002/0040199 A1	4/2002	Klopotek	2004/0042168 A1	3/2004	Yang et al.
2002/0040442 A1	4/2002	Ishidera	2004/0044375 A1	3/2004	Diederich et al.
2002/0055702 A1	5/2002	Atala	2004/0049134 A1	3/2004	Tosaya et al.
2002/0062077 A1	5/2002	Emmenegger	2004/0059266 A1	3/2004	Fry
2002/0062142 A1	5/2002	Knowlton	2004/0068186 A1	4/2004	Ishida et al.
2002/0072691 A1	6/2002	Thompson et al.	2004/0073079 A1	4/2004	Altshuler et al.
2002/0082528 A1	6/2002	Friedman	2004/0073113 A1	4/2004	Salgo
2002/0082529 A1	6/2002	Suorsa et al.	2004/0073115 A1 *	4/2004	Horzewski ..... H04N 1/58 600/439
2002/0082589 A1	6/2002	Friedman	2004/0073116 A1	4/2004	Smith
2002/0087080 A1	7/2002	Slayton	2004/0073204 A1	4/2004	Ryan et al.
2002/0095143 A1	7/2002	Key	2004/0077977 A1	4/2004	Ella et al.
2002/0099094 A1	7/2002	Anderson	2004/0082857 A1	4/2004	Schonenberger
2002/0115917 A1	8/2002	Honda et al.	2004/0082859 A1	4/2004	Schaer
2002/0128639 A1	9/2002	Pless et al.	2004/0102697 A1	5/2004	Evron
2002/0128648 A1	9/2002	Weber	2004/0105559 A1	6/2004	Aylward et al.
2002/0143252 A1	10/2002	Dunne et al.	2004/0106867 A1	6/2004	Eshel et al.
2002/0156400 A1	10/2002	Babaev	2004/0122323 A1	6/2004	Vortman et al.
2002/0161357 A1	10/2002	Anderson	2004/0122493 A1	6/2004	Ishibashi et al.
2002/0165529 A1	11/2002	Danek	2004/0143297 A1	7/2004	Ramsey
2002/0168049 A1	11/2002	Schriever	2004/0152982 A1	8/2004	Hwang et al.
2002/0169394 A1	11/2002	Eppstein et al.	2004/0158150 A1	8/2004	Rabiner et al.
2002/0169442 A1	11/2002	Neev	2004/0186535 A1	9/2004	Knowlton
2002/0173721 A1	11/2002	Grunwald et al.	2004/0189155 A1	9/2004	Funakubo
2002/0193784 A1 *	12/2002	McHale ..... A61K 41/00 606/27	2004/0206365 A1	10/2004	Knowlton
2002/0193831 A1	12/2002	Smith	2004/0210214 A1	10/2004	Knowlton
2003/0009153 A1	1/2003	Briskin et al.	2004/0217675 A1 *	11/2004	Desilets ..... A61B 8/00 310/367
2003/0014039 A1	1/2003	Barzell et al.	2004/0249318 A1	12/2004	Tanaka
2003/0018255 A1	1/2003	Martin	2004/0254620 A1	12/2004	Lacoste
2003/0028111 A1	2/2003	Vaezy et al.	2004/0267252 A1	12/2004	Washington et al.
2003/0028113 A1	2/2003	Gilbert et al.	2005/0033201 A1	2/2005	Takahashi
2003/0032900 A1	2/2003	Ella	2005/0033316 A1	2/2005	Kertz
2003/0036706 A1	2/2003	Slayton et al.	2005/0038340 A1	2/2005	Vaezy et al.
2003/0040739 A1	2/2003	Koop	2005/0055018 A1	3/2005	Kreindel
2003/0050678 A1	3/2003	Sierra	2005/0055073 A1	3/2005	Weber
2003/0055417 A1	3/2003	Truckai et al.	2005/0061834 A1	3/2005	Garcia et al.
2003/0060736 A1	3/2003	Martin et al.	2005/0070961 A1	3/2005	Maki
2003/0065313 A1	4/2003	Koop	2005/0074407 A1	4/2005	Smith
2003/0073907 A1	4/2003	Taylor	2005/0080469 A1	4/2005	Larson
			2005/0091770 A1	5/2005	Mourad et al.
			2005/0096542 A1	5/2005	Weng et al.
			2005/0104690 A1	5/2005	Larson et al.
			2005/0113689 A1	5/2005	Gritzky

(56)

## References Cited

## U.S. PATENT DOCUMENTS

2005/0131302	A1	6/2005	Poland	2007/0239077	A1	10/2007	Azhari et al.
2005/0137656	A1	6/2005	Malak	2007/0239079	A1	10/2007	Manstein et al.
2005/0143677	A1	6/2005	Young et al.	2007/0239142	A1	10/2007	Altshuler
2005/0154313	A1	7/2005	Desilets	2008/0027328	A1	1/2008	Klopotek
2005/0154314	A1	7/2005	Quistgaard	2008/0039724	A1	2/2008	Seip et al.
2005/0154332	A1	7/2005	Zanelli	2008/0071255	A1	3/2008	Barthe
2005/0154431	A1	7/2005	Quistgaard	2008/0086054	A1	4/2008	Slayton
2005/0187495	A1	8/2005	Quistgaard	2008/0086056	A1	4/2008	Chang et al.
2005/0191252	A1	9/2005	Mitsui	2008/0097214	A1	4/2008	Meyers et al.
2005/0193451	A1	9/2005	Quistgaard	2008/0097253	A1	4/2008	Pedersen et al.
2005/0197681	A1	9/2005	Barolet et al.	2008/0114251	A1	5/2008	Weymer et al.
2005/0228281	A1	10/2005	Nefos	2008/0139974	A1	6/2008	Da Silva
2005/0240170	A1	10/2005	Zhang et al.	2008/0146970	A1	6/2008	Litman et al.
2005/0251120	A1*	11/2005	Anderson	2008/0167556	A1	7/2008	Thompson
			..... A61B 5/6804	2008/0183077	A1	7/2008	Moreau-Gobard et al.
			606/20	2008/0183110	A1	7/2008	Davenport et al.
2005/0251125	A1	11/2005	Pless et al.	2008/0188745	A1	8/2008	Chen et al.
2005/0256406	A1	11/2005	Barthe	2008/0194964	A1	8/2008	Randall et al.
2005/0261584	A1	11/2005	Eshel	2008/0195000	A1	8/2008	Spooner et al.
2005/0261585	A1	11/2005	Makin et al.	2008/0200810	A1	8/2008	Buchalter
2005/0267454	A1	12/2005	Hissong	2008/0200813	A1	8/2008	Quistgaard
2005/0288748	A1	12/2005	Li et al.	2008/0214966	A1	9/2008	Slayton
2006/0004306	A1	1/2006	Altshuler	2008/0221491	A1	9/2008	Slayton
2006/0020260	A1	1/2006	Dover et al.	2008/0223379	A1	9/2008	Stuker et al.
2006/0025756	A1	2/2006	Francischelli	2008/0242991	A1	10/2008	Moon et al.
2006/0042201	A1	3/2006	Curry	2008/0243035	A1	10/2008	Crunkilton
2006/0058664	A1	3/2006	Barthe	2008/0269608	A1	10/2008	Anderson et al.
2006/0058671	A1	3/2006	Vitek et al.	2008/0275342	A1	11/2008	Barthe
2006/0058707	A1	3/2006	Barthe	2008/0281206	A1	11/2008	Bartlett et al.
2006/0058712	A1	3/2006	Altshuler et al.	2008/0281236	A1	11/2008	Eshel et al.
2006/0074309	A1	4/2006	Bonnefous	2008/0281237	A1	11/2008	Slayton
2006/0074313	A1	4/2006	Slayton et al.	2008/0281255	A1	11/2008	Slayton
2006/0074314	A1	4/2006	Slayton	2008/0294073	A1	11/2008	Barthe
2006/0074355	A1	4/2006	Slayton	2008/0319356	A1	12/2008	Cain
2006/0079816	A1	4/2006	Barthe	2009/0005680	A1	1/2009	Jones et al.
2006/0079868	A1	4/2006	Makin	2009/0012394	A1	1/2009	Hobelsberger et al.
2006/0084891	A1	4/2006	Barthe	2009/0043198	A1	2/2009	Milner et al.
2006/0089632	A1	4/2006	Barthe	2009/0043293	A1	2/2009	Pankratov et al.
2006/0089688	A1	4/2006	Panescu	2009/0048514	A1	2/2009	Azhari et al.
2006/0094988	A1	5/2006	Tosaya	2009/0069677	A1	3/2009	Chen et al.
2006/0111744	A1	5/2006	Makin	2009/0093737	A1	4/2009	Chomas et al.
2006/0116583	A1	6/2006	Ogasawara et al.	2009/0156969	A1	6/2009	Santangelo
2006/0116671	A1	6/2006	Slayton	2009/0171252	A1	7/2009	Bockenstedt et al.
2006/0122508	A1	6/2006	Slayton	2009/0177122	A1	7/2009	Peterson
2006/0122509	A1	6/2006	Desilets	2009/0177123	A1	7/2009	Peterson
2006/0161062	A1	7/2006	Arditi et al.	2009/0182231	A1	7/2009	Barthe et al.
2006/0184069	A1	8/2006	Vaitekunas	2009/0198157	A1	8/2009	Babaev et al.
2006/0184071	A1	8/2006	Klopotek	2009/0216159	A1	8/2009	Slayton et al.
2006/0189972	A1	8/2006	Grossman	2009/0226424	A1	9/2009	Hsu
2006/0206105	A1	9/2006	Chopra	2009/0227910	A1	9/2009	Pedersen et al.
2006/0229514	A1	10/2006	Wiener	2009/0253988	A1	10/2009	Slayton et al.
2006/0241440	A1	10/2006	Eshel	2009/0281463	A1	11/2009	Chapelon et al.
2006/0241442	A1	10/2006	Barthe	2009/0312693	A1	12/2009	Thapliyal et al.
2006/0241470	A1	10/2006	Novak et al.	2009/0318909	A1	12/2009	Debenedictis et al.
2006/0241576	A1	10/2006	Diederich et al.	2010/0011236	A1	1/2010	Barthe et al.
2006/0250046	A1	11/2006	Koizumi et al.	2010/0022919	A1	1/2010	Peterson
2006/0282691	A1	12/2006	Barthe	2010/0022921	A1	1/2010	Seip et al.
2006/0291710	A1	12/2006	Wang et al.	2010/0022922	A1	1/2010	Barthe et al.
2007/0032784	A1	2/2007	Gilklich et al.	2010/0030076	A1	2/2010	Vortman et al.
2007/0035201	A1	2/2007	Desilets	2010/0042020	A1	2/2010	Ben-Ezra
2007/0055154	A1	3/2007	Torbati	2010/0049178	A1	2/2010	Deem et al.
2007/0055155	A1	3/2007	Owen et al.	2010/0056925	A1	3/2010	Zhang et al.
2007/0055156	A1	3/2007	Desilets et al.	2010/0100014	A1	4/2010	Eshel et al.
2007/0065420	A1	3/2007	Johnson	2010/0113983	A1	5/2010	Heckerman et al.
2007/0083120	A1	4/2007	Cain et al.	2010/0130891	A1	5/2010	Taggart et al.
2007/0087060	A1	4/2007	Dietrich	2010/0160782	A1	6/2010	Slayton et al.
2007/0088245	A1	4/2007	Babaev et al.	2010/0160837	A1	6/2010	Hunziker et al.
2007/0088346	A1	4/2007	Mirizzi et al.	2010/0168576	A1	7/2010	Poland et al.
2007/0161902	A1	7/2007	Dan	2010/0191120	A1	7/2010	Kraus et al.
2007/0166357	A1	7/2007	Shaffer et al.	2010/0241035	A1	9/2010	Barthe et al.
2007/0167709	A1	7/2007	Slayton	2010/0249602	A1	9/2010	Buckley et al.
2007/0208253	A1	9/2007	Slayton	2010/0249669	A1	9/2010	Ulric et al.
2007/0219604	A1	9/2007	Yaroslavsky et al.	2010/0256489	A1	10/2010	Pedersen et al.
2007/0219605	A1	9/2007	Yaroslavsky et al.	2010/0274161	A1	10/2010	Azhari et al.
2007/0238994	A1	10/2007	Stecco et al.	2010/0280420	A1	11/2010	Barthe et al.
2007/0239075	A1	10/2007	Rosenberg	2010/0286518	A1	11/2010	Lee et al.
				2010/0312150	A1	12/2010	Mast et al.
				2011/0040171	A1	2/2011	Foley et al.
				2011/0040190	A1	2/2011	Jahnke et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

2011/0066084	A1	3/2011	Desilets et al.	2014/0180174	A1	6/2014	Slayton et al.
2011/0087099	A1	4/2011	Eshel et al.	2014/0187944	A1	7/2014	Slayton et al.
2011/0087255	A1	4/2011	McCormack et al.	2014/0188015	A1	7/2014	Slayton et al.
2011/0112405	A1	5/2011	Barthe et al.	2014/0188145	A1	7/2014	Slayton et al.
2011/0144490	A1	6/2011	Davis et al.	2014/0194723	A1	7/2014	Herzog et al.
2011/0178444	A1	7/2011	Slayton et al.	2014/0208856	A1	7/2014	Schmid
2011/0178541	A1	7/2011	Azhari	2014/0221823	A1	8/2014	Keogh et al.
2011/0190745	A1	8/2011	Uebelhoefer et al.	2014/0236049	A1	8/2014	Barthe et al.
2011/0251524	A1	10/2011	Azhari et al.	2014/0236061	A1	8/2014	Lee et al.
2011/0251527	A1	10/2011	Kushculey et al.	2014/0243713	A1	8/2014	Slayton et al.
2011/0270137	A1	11/2011	Goren et al.	2014/0257145	A1	9/2014	Emery
2011/0319793	A1	12/2011	Hynynen	2014/0276055	A1	9/2014	Barthe et al.
2012/0004549	A1	1/2012	Barthe et al.	2015/0000674	A1	1/2015	Barthe et al.
2012/0016239	A1	1/2012	Barthe et al.	2015/0080723	A1	3/2015	Barthe et al.
2012/0029353	A1	2/2012	Slayton et al.	2015/0080771	A1	3/2015	Barthe et al.
2012/0035475	A1	2/2012	Barthe et al.	2015/0080874	A1	3/2015	Slayton et al.
2012/0035476	A1	2/2012	Barthe et al.	2015/0088182	A1	3/2015	Slayton et al.
2012/0046547	A1	2/2012	Barthe et al.	2015/0164734	A1	6/2015	Slayton et al.
2012/0053458	A1	3/2012	Barthe et al.	2015/0165238	A1	6/2015	Slayton et al.
2012/0111339	A1	5/2012	Barthe et al.	2015/0165243	A1	6/2015	Slayton et al.
2012/0123304	A1	5/2012	Rybyanets et al.	2015/0174388	A1	6/2015	Slayton
2012/0136280	A1	5/2012	Rosenberg et al.				
2012/0136282	A1	5/2012	Rosenberg et al.				
2012/0143056	A1	6/2012	Slayton et al.				
2012/0143100	A1	6/2012	Jeong et al.				
2012/0165668	A1	6/2012	Slayton et al.				
2012/0165848	A1	6/2012	Slayton et al.				
2012/0191020	A1	7/2012	Vitek et al.				
2012/0197120	A1	8/2012	Makin et al.				
2012/0197121	A1	8/2012	Slayton et al.				
2012/0209150	A1	8/2012	Zeng et al.				
2012/0215105	A1	8/2012	Slayton et al.				
2012/0271202	A1	10/2012	Wisdom				
2012/0271294	A1	10/2012	Barthe et al.				
2012/0296240	A1	11/2012	Azhari et al.				
2012/0302883	A1	11/2012	Kong et al.				
2012/0316426	A1	12/2012	Foley et al.				
2012/0330197	A1	12/2012	Makin et al.				
2012/0330222	A1	12/2012	Makin et al.				
2012/0330223	A1	12/2012	Makin et al.				
2012/0330283	A1	12/2012	Hyde et al.				
2012/0330284	A1	12/2012	Hyde et al.				
2013/0012755	A1	1/2013	Slayton				
2013/0012816	A1	1/2013	Slayton et al.				
2013/0012838	A1	1/2013	Jaeger et al.				
2013/0012842	A1	1/2013	Barthe				
2013/0018285	A1	1/2013	Park et al.				
2013/0018286	A1	1/2013	Slayton et al.				
2013/0046209	A1	2/2013	Slayton et al.				
2013/0051178	A1	2/2013	Rybyanets				
2013/0060170	A1	3/2013	Lee et al.				
2013/0066208	A1	3/2013	Barthe et al.				
2013/0066237	A1	3/2013	Smotrich et al.				
2013/0072826	A1	3/2013	Slayton et al.				
2013/0096471	A1	4/2013	Slayton et al.				
2013/0190659	A1	7/2013	Slayton et al.				
2013/0211293	A1	8/2013	Auboiroux et al.				
2013/0225994	A1	8/2013	Hsu et al.				
2013/0274603	A1	10/2013	Barthe et al.				
2013/0281853	A1	10/2013	Slayton et al.				
2013/0281891	A1	10/2013	Slayton et al.				
2013/0296697	A1	11/2013	Slayton et al.				
2013/0296700	A1	11/2013	Slayton et al.				
2013/0303904	A1	11/2013	Barthe et al.				
2013/0303905	A1	11/2013	Barthe et al.				
2013/0310714	A1	11/2013	Eshel et al.				
2013/0310863	A1	11/2013	Makin et al.				
2013/0345562	A1	12/2013	Barthe et al.				
2014/0024974	A1	1/2014	Slayton et al.				
2014/0050054	A1	2/2014	Toda et al.				
2014/0081300	A1	3/2014	Melodelima et al.				
2014/0082907	A1	3/2014	Barthe et al.				
2014/0117814	A1	5/2014	Toda et al.				
2014/0142430	A1	5/2014	Slayton et al.				
2014/0148834	A1	5/2014	Barthe et al.				

## FOREIGN PATENT DOCUMENTS

DE	10140064	3/2003
DE	10219297	11/2003
DE	10219217	12/2004
DE	20314479	12/2004
EP	0142215	5/1984
EP	0344773	12/1989
EP	1479412	11/1991
EP	0473553	4/1992
EP	0661029	7/1995
EP	1044038	10/2000
EP	1050322	11/2000
EP	1234566	8/2002
EP	1262160	12/2002
EP	1283690	2/2003
EP	1374944	1/2004
EP	1028660	1/2008
EP	1874241	1/2008
EP	1362223	5/2008
EP	1750804	7/2008
EP	1811901	4/2009
EP	1785164	8/2009
EP	2230904	9/2010
EP	1501331	6/2011
EP	2066405	11/2011
EP	2474050	7/2012
FR	2672486	8/1992
GB	2113099	8/1983
JP	63036171	2/1988
JP	03048299	3/1991
JP	3123559	5/1991
JP	03136642	6/1991
JP	4089058	3/1992
JP	4-150847	5/1992
JP	04150847	5/1992
JP	7080087	3/1995
JP	07505793	6/1995
JP	2007505793	6/1995
JP	7222782	8/1995
JP	09047458	2/1997
JP	9108288	4/1997
JP	9503926	4/1997
JP	11-505440	5/1999
JP	11-506636	6/1999
JP	2000166940	6/2000
JP	2001170068	6/2001
JP	2002-505596	2/2002
JP	2002078764	3/2002
JP	2002515786	5/2002
JP	2002521118	7/2002
JP	2002-537939	11/2002
JP	2003050298	7/2003
JP	2003204982	7/2003
JP	2004-147719	5/2004
JP	2005503388	2/2005
JP	2005527336	9/2005



(56)

## References Cited

## FOREIGN PATENT DOCUMENTS

JP	2005323213	11/2005
JP	2006520247	9/2006
JP	2008515559	5/2008
JP	2009518126	5/2009
JP	2010517695	5/2010
KR	1020010024871	3/2001
KR	100400870	10/2003
KR	1020060113930	11/2006
KR	1020070065332	6/2007
KR	1020070070161	7/2007
KR	1020070098856	10/2007
KR	1020070104878	10/2007
KR	1020070114105	11/2007
KR	1020000059516	4/2012
WO	WO 96/25888	8/1996
WO	WO9634568	11/1996
WO	WO 96/39079	12/1996
WO	WO 9735518	10/1997
WO	WO 9832379	7/1998
WO	WO 98/52465	11/1998
WO	WO 9933520	7/1999
WO	WO 9949788	10/1999
WO	WO 0006032	2/2000
WO	WO 0015300	3/2000
WO	WO 0021612	4/2000
WO	WO 0053113	9/2000
WO	WO 0128623	4/2001
WO	WO 0182777	11/2001
WO	WO 0182778	11/2001
WO	WO 0187161	11/2001
WO	WO0187161	11/2001
WO	WO 0209813	2/2002
WO	WO 0224050	3/2002
WO	WO02054018	7/2002
WO	WO 02092168	11/2002
WO	WO 03/053266	7/2003
WO	WO 03065347	8/2003
WO	WO 03070105	8/2003
WO	WO 03077833	9/2003
WO	WO 03086215	10/2003
WO	WO 03/096883	11/2003
WO	WO 03/099382	12/2003
WO	WO 03099177	12/2003
WO	WO 03101530	12/2003
WO	WO 2004000116	12/2003
WO	WO 2004080147	9/2004
WO	WO 2004110558	12/2004
WO	WO 2005011804	2/2005
WO	WO 2005065408	7/2005
WO	WO 2005090978	9/2005
WO	WO2005113068	12/2005
WO	WO 2006036870	4/2006
WO	WO 2006042163	4/2006
WO	WO 2006042168	4/2006
WO	WO 2006042201	4/2006
WO	WO 2006065671	6/2006
WO	WO 2006082573	8/2006
WO	WO 2007067563	6/2007
WO	WO 2008036622	3/2008
WO	WO2008036479	11/2008
WO	WO 2009013729	1/2009
WO	WO2009/149390	10/2009
WO	WO2008144274	1/2010
WO	WO2012134645	10/2012
WO	WO2014045216	3/2014
WO	WO2014/055708	4/2014
WO	WO2014057388	4/2014

## OTHER PUBLICATIONS

Arthur et al., "Non-invasive estimation of hyperthermia temperatures with ultrasound," *Int. J. Hyperthermia*, Sep. 2005, 21(6), pp. 589-600.

Barthe et al., "Ultrasound therapy system and ablation results utilizing miniature imaging/therapy arrays," *Ultrasonics Symposium*, 2004 IEEE, Aug. 23, 2004, pp. 1792-1795, vol. 3.

Calderhead et al., "One Mechanism Behind LED Photo-Therapy for Wound Healing and Skin Rejuvenation: Key Role of the Mast Cell" *Laser Therapy* 17.3: 141-148 (2008).

Chen, L. et al., "Effect of Blood Perfusion on the ablation of liver parenchyma with high intensity focused ultrasound," *Phys. Med. Biol.* 38:1661-1673; 1993b.

Coon, Joshua et al., "Protein identification using sequential ion/ion reactions and tandem mass spectrometry" *Proceedings of the National Academy of Sciences of the USA*, vol. 102, No. 27, Jul. 27, 2005, pp. 9463-9468.

Corry, Peter M., et al., "Human Cancer Treatment with Ultrasound", *IEEE Transactions on Sonics and Ultrasonics*, vol. SU-31, No. 5, Sep. 1984, pp. 444, 456.

Damianou et al., "Application of the Thermal Dose Concept for Predicting the Necrosed Tissue Volume During Ultrasound Surgery," 1993 IEEE Ultrasound Symposium, pp. 1199-1202.

Daum et al., Design and Evaluation of a Feedback Based Phased Array System for Ultrasound Surgery, *IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control*, vol. 45, No. 2, Mar. 1998, pp. 431-438.

Davis, Brian J., et al., "An Acoustic Phase Shift Technique for the Non-Invasive Measurement of Temperature Changes in Tissues", 1985 Ultrasonics Symposium, pp. 921-924.

Decision of the Korean Intellectual Property Tribunal dated Jun. 28, 2013 regarding Korean Patent No. 10-1142108, which is related to the pending application and/or an application identified in the Table on pp. 1-4 of the Information Disclosure Statement herein (English translation, English translation certification, and Korean decision included).

Fry, W.J. et al., "Production of Focal Destructive Lesions in the Central Nervous System with Ultrasound," *J. Neurosurg.*, 11:471-478; 1954.

Gliklich et al., Clinical Pilot Study of Intense Ultrasound therapy to Deep Dermal Facial Skin and Subcutaneous Tissues, *Arch Facial Plastic Surgery*, Mar. 1, 2007, vol. 9, No. 1.

Haar, G.R. et al., "Tissue Destruction with Focused Ultrasound in Vivo," *Eur. Urol.* 23 (suppl. 1):8-11; 1993.

Hassan et al., "Structure and Applications of Poly(vinyl alcohol) Hydrogels Produced by Conventional Crosslinking or by Freezing/Thawing Methods," *advanced in Polymer Science*, 2000, pp. 37-65, vol. 153.

Hassan et al., "Structure and Morphology of Freeze/Thawed PVA Hydrogels," *Macromolecules*, Mar. 11, 2000, pp. 2472-2479, vol. 33, No. 7.

Hussein et al., "The Role of Cavitation in Acoustically Activated Drug Delivery," *J. Control Release*, Oct. 3, 2005, pp. 253-261, vol. 107(2).

Hussein et al. "Investigating the mechanism of acoustically activated uptake of drugs from Pluronic micelles," *Bmd Cancer* 2002, 2:20k, Aug. 30, 2002, pp. 1-6.

Jeffers et al., "Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms," 1993 IEEE Ultrasonics Symposium, pp. 925-928.

Jenne, J., et al., "Temperature Mapping for High Energy US-Therapy", 1994 Ultrasonics Symposium, pp. 1879-1882.

Johnson, S.A., et al., "Non-Intrusive Measurement of Microwave and Ultrasound-Induced Hyperthermia by Acoustic Temperature Tomography", *Ultrasonics Symposium Proceedings*, pp. 977-982. (1977).

Madersbacher, S. et al., "Tissue Ablation in Benign Prostatic Hyperplasia with High Intensity Focused Ultrasound," *Dur. Urol.*, 23 (suppl. 1):39-43; 1993.

Makin et al., "B-Scan Imaging and Thermal Lesion Monitoring Using Miniaturized Dual-Functionality Ultrasound Arrays," *Ultrasonics Symposium*, 2004 IEEE, Aug. 23, 2004, pp. 1788-1791, vol. 3.

Makin et al., "Confirmed Bulk Ablation and Therapy Monitoring Using Intracorporeal Image-Treat Ultrasound Arrays," 4th International Symposium on Therapeutic Ultrasound, Sep. 19, 2004.


(56)

## References Cited

## OTHER PUBLICATIONS

- Makin et al., "Miniaturized Ultrasound Arrays for Interstitial Ablation and Imaging," *UltraSound Med. Biol.* 2005, Nov. 1, 2005, pp. 1539-1550, vol. 31(11).
- Manohar et al., "Photoacoustic mammography laboratory prototype: imaging of breast tissue phantoms," *Journal of Biomedical Optics*, Nov./Dec. 2004, pp. 1172-1181, vol. 9, No. 6.
- Mast et al., "Bulk Ablation of Soft Tissue with Intense Ultrasound; Modeling and Experiments," *J. Acoust. Soc. Am.*, Oct. 1, 2005, pp. 2715-2724, vol. 118(4).
- Mitragotri, S., "Healing sound: the use of ultrasound in drug delivery and other therapeutic applications," *Nature Reviews; Drug Delivery*, pp. 255-260, vol. 4 (Mar. 2005).
- Paradossi et al., "Poly(vinyl alcohol) as versatile biomaterial for potential biomedical applications," *Journal of Materials Science: Materials in Medicine*, 2003, pp. 687-691, vol. 14.
- Reid, Gavin, et al., "Tandem Mass spectrometry of ribonuclease A and B: N-linked glycosylation site analysis of whole protein ions," *Analytical Chemistry*, Feb. 1, 2002, vol. 74, No. 3, pp. 577-583.
- Righetti et al., "Elastographic Characterization of HIFU-Induced Lesions in Canine Livers," 1999, *Ultrasound in Med & Bio*, vol. 25, No. 7, pp. 1099-1113.
- Saad et al., "Ultrasound-Enhanced Effects of Adriamycin Against Murine Tumors," *Ultrasound in Med. & Biol.* vol. 18, No. 8, pp. 715-723 (1992).
- Sanghvi, N.T., et al., "Transrectal Ablation of Prostate Tissue Using Focused Ultrasound," 1993 *Ultrasonics Symposium*, IEEE, pp. 1207-1210.
- Sassen, Sander, "ATI's R520 architecture, the new king of the hill?" <http://www.hardwareanalysis.com/content/article/1813>, Sep. 16, 2005, 2 pages.
- Seip, Ralf, et al., "Noninvasive Detection of Thermal Effects Due to Highly Focused Ultrasonic Fields," *IEEE Symposium*, pp. 1229-1232, vol. 2, Oct. 3-Nov. 1993.
- Seip, Ralf, et al., "Noninvasive Estimation of Tissue Temperature Response to Heating Fields Using Diagnostic Ultrasound," *IEEE Transactions on Biomedical Engineering*, vol. 42, No. 8, Aug. 1995, pp. 828-839.
- Simon et al., "Applications of Lipid-Coated Microbubble Ultrasound Contrast to Tumor Therapy," *Ultrasound in Med. & Biol.* vol. 19, No. 2, pp. 123-125 (1993).
- Smith, Nadine Barrie, et al., "Non-invasive In Vivo Temperature Mapping of Ultrasound Heating Using Magnetic Resonance Techniques," 1994 *Ultrasonics Symposium*, pp. 1829-1832, vol. 3.
- Surry et al., "Poly(vinyl alcohol) cryogel phantoms for use in ultrasound and MR imaging," *Phys. Med. Biol.*, Dec. 6, 2004, pp. 5529-5546, vol. 49.
- Syka J. E. P. et al., "Peptide and Protein Sequence Analysis by Electron Transfer Dissociation Mass Spectrometry," *Proceedings of the National Academy of Sciences of USA*, National Academy of Science, Washington, DC, vol. 101, No. 26, Jun. 29, 2004, pp. 9528-9533.
- Talbert, D. G., "An Add-On Modification for Linear Array Real-Time Ultrasound Scanners to Produce 3D Displays," *UTS Int'l 1977 Brighton, England* (Jun. 28-30, 1977) pp. 57-67.
- Tata et al., "Interaction of Ultrasound and Model Membrane Systems: Analyses and Predictions," *American Chemical Society, Phys. Chem.* 1992, 96, pp. 3548-3555.
- Ueno, S., et al., "Ultrasound Thermometry in Hyperthermia," 1990 *Ultrasonic Symposium*, pp. 1645-1652.
- Wang, H., et al., "Limits on Focused Ultrasound for Deep Hyperthermia," 1994 *Ultrasonic Symposium*, Nov. 1-4, 1994, pp. 1869-1872, vol. 3.
- Wasson, Scott, "NVIDIA's GeForce 7800 GTX graphics processor Power MADD," <http://techreport.com/reviews/2005q2/geforce-7800gtx/index.x?pg=1>, Jun. 22, 2005, 4 pages.
- White et al "Selective Creating of Thermal Injury Zones in the Superficial Musculoaponeurotic System Using Intense Ultrasound Therapy," *Arch Facial Plastic Surgery*, Jan./Feb. 2007, vol. 9, No. 1.
- Agren, Magnus S. et al., *Collagenase in Wound Healing: Effect of Wound Age and Type*. The Journal of Investigative Dermatology, vol. 99/No. 6, (Dec. 1992).
- Bozec, Laurent et al., *Thermal Denaturation Studies of Collagen by Microthermal Analysis and Atomic Force Microscopy*, *Biophysical Journal*, vol. 101, pp. 228-236. (Jul. 2001).
- Dierickx, Christine C., "The Role of Deep Heating for Noninvasive Skin Rejuvenation" *Lasers in Surgery and Medicine* 38:799-807 (2006).
- Dong, Yuan-Lin et al., "Effect of Ibuprofen on the Inflammatory Response to Surgical Wounds" *The Journal of Trauma*, vol. 35, No. 3. (1993).
- Dvivedi, Sanjay, et al. "Effect of Ibuprofen and diclofenac sodium on experimental wound healing" *Indian Journal of Experimental Biology*, vol. 35, pp. 1243-1245. (Nov. 1997).
- Greenhalgh, David G., "Wound healing and diabetes mellitus" *Clinics in Plastic Surgery* 30; 37-45. (2003).
- Guo, S. et al., "Factors Affecting Wound Healing" *Critical Reviews in Oral Biology & Medicine*, *J Dent Res* 89(3), pp. 219-229. (2010).
- Hantash, Basil M. et al., "Bipolar Fractional Radiofrequency Treatment Induces Neoeelastogenesis and Neocollagenesis" *Lasers in Surgery and Medicine* 41:1-9 (2009).
- Hantash, Basil M. et al., "In Vivo Histological Evaluation of a Novel Ablative Fractional Resurfacing Device" *Lasers in Surgery and Medicine* 39:96-107 (2007).
- Krischak, G.D., et al., "The effects of non-steroidal anti-inflammatory drug application on incisional wound healing in rats" *Journal of Wound Care*, vol. 6, No. 2, (Feb. 2007).
- Lin, Sung-Jan, et al., "Monitoring the thermally induced structural transitions of collagen by use of second-harmonic generation microscopy" *Optics Letters*, vol. 30, No. 6, (Mar. 15, 2005).
- Meshkinpour, Azin, et al., "Treatment of Hypertrophic Scars and Keloids With a Radiofrequency Device: A Study of Collagen Effects" *Lasers in Surgery and Medicine* 37:343-349 (2005).
- Mosser, David M. et al., "Exploring the full spectrum of macrophage activation" *Nat Rev Immunol*; 8(12): 958-969. (Dec. 2008).
- Murota, Sei-Itsu, et al., "Stimulatory Effect of Prostaglandins on the Production of Hexosamine-Containing Substances by Cultured Fibroblasts (3) Induction of Hyaluronic Acid Synthetase by Prostaglandin" *Department of Pharmacology, Tokyo Metropolitan Institute of Gerontology, Itabashiku, Tokyo-173, Japan.* (Nov. 1977, vol. 14, No. 5).
- Murota, Sei-Itsu, et al., "The Stimulatory Effect of Prostaglandins on Production of Hexosamine-Containing Substances by Cultured Fibroblasts" *Department of Pharmacology, Tokyo Metropolitan Institute of Gerontology, Itabashiku, Tokyo-173, Japan.* (Aug. 1976, vol. 12, No. 2).
- Rappolee, Daniel A., et al., "Wound Macrophages Express TGF and Other Growth Factors in Vivo: Analysis by mRNA Phenotyping" *Science*, vol. 241, No. 4866 (Aug. 1988).
- Rosenberg, Carol S. "Wound Healing in the Patient with Diabetes Mellitus" *Nursing Clinics of North America*, vol. 25, No. 1, (Mar. 1990).
- Sandulache, Vlad C. et al., "Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)—B1—induced collagen synthesis" *Wound Rep Reg* 15 122-133, 2007.
- Suh, Dong Hye et al., "Intense Focused Ultrasound Tightening in Asian Skin: Clinical and Pathologic Results" *American Society for Dermatologic Surgery, Inc.*; 37:1595-1602. (2011).
- Verhofstad, Michiel H.J. et al., "Collagen Synthesis in rat skin and ileum fibroblasts is affected differently by diabetes-related factors" *Int. J. Exp. Path.* (1998), 79, 321-328.
- White, W. Matthew, et al., "Selective Transcutaneous Delivery of Energy to Porcine Soft Tissues Using Intense Ultrasound (IUS)" *Lasers in Surgery and Medicine* 40:67-75 (2008).
- Zelickson, Brian D. et al., "Histological and Ultrastructural Evaluation of the Effects of a Radiofrequency-Based Nonablative Dermal Remodeling Device, A Pilot Study" *Arch Dermatol*, vol. 140, (Feb. 2004).

\* cited by examiner

**FIG. 1**




FIG. 2A




FIG. 2B




FIG. 2C









FIG. 2D

**FIG. 3A**



300  
**FIG. 3B**

**FIG. 4A**

**FIG. 4B**






FIG. 5

**FIG. 6A**

**FIG. 6B**




FIG. 7




FIG. 8A





FIG. 8B



**FIG. 9**





FIG. 10A

**FIG. 10B**




FIG. 10C




FIG. 10D




FIG. 10E




FIG. 10F





FIG. 11

**FIG. 12**




FIG. 13



## SYSTEMS FOR TREATING SKIN LAXITY

INCORPORATION BY REFERENCE TO ANY  
PRIORITY APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 14/169,709, which is a continuation of U.S. patent application Ser. No. 13/230,498, issued as U.S. Pat. No. 8,641,622, which is a continuation of U.S. patent application Ser. No. 11/163,150, issued as U.S. Pat. No. 8,066,641, which claims the benefit of priority to U.S. Provisional Application No. 60/617,295, each of which is incorporated in its entirety by reference herein. Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 CFR 1.57.

## BACKGROUND

The present invention relates to ultrasound therapy and imaging systems, and in particular to a method and system for treating photoaged tissue.

Photoaging of human skin is a complex response due to inflammation, oxidative injury, cellular and extracellular changes induced by decades of sunlight exposure. UV wavelengths are thought to be mainly responsible. Both of the primary skin layers, epidermis and dermis, are affected. Epidermal photoaging includes pigmentary lesions called ephelides (freckles) and solar lentigines (larger pigmented spots), plus precancerous clonal lesions of keratinocytes called actinic keratoses. Thermal destruction of part or all of the epidermis, the outermost cellular layer of skin about 0.1 mm thick, is an effective treatment for epidermal photoaging. For example, lasers that vaporize epidermis are highly effective in a treatment called laser resurfacing. However laser resurfacing creates a significant skin wound with risk of infection, and prolonged healing. Dermal changes of photoaging include solar elastosis (an accumulation of abnormally-formed elastin fibers in the upper reticular layer of the dermis), laxity, loss of elasticity, fine and coarse wrinkles. Laser resurfacing to a depth below the dermoepidermal junction can be highly effective for improving dermal photoaging, through a process of stimulated wound healing. Deep chemical peels, dermabrasion and other methods of destruction of epidermis and/or dermis are also effective, and also produce a significant open skin wound with risk of infection and delayed healing.

Patterns of stimulated thermal damage to epidermis and/or dermis are also effective for treatment of photoaging. Recently, "fractional photothermolysis" using mid-infrared lasers to produce a microscopic array of thermal injury zones that include both epidermis and dermis was reported to be effective and well-tolerated for treatment of photoaging (D. Manstein et al. "Fractional Photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury." *Lasers Surg Med* 34:426-438, 2004). A primary advantage of fractional photothermolysis is that each zone of thermal injury is smaller than can be easily seen with the unaided eye, and surrounded by a zone of healthy tissue that initiates a rapid healing response. As described Manstein, the epidermis is stimulated to heal rapidly and without creating an open wound. The microscopic zones of thermally injured epidermis slough harmlessly from the skin surface after several days to several weeks, leaving a rejuvenated epidermis with less photoaging changes. Repeat treatments, which are well tolerated, can be

performed until a desired result is obtained. The microscopic zones of thermal injury with fractional photothermolysis extend well into the dermis, as well. Dermis does not heal as rapidly as epidermis, in general. Over weeks to months following treatment, some of the abnormal dermis due to photoaging is remodeled, however, leading to improvement in laxity, wrinkles and skin texture.

Fractional photothermolysis (FP) is intrinsically limited to regions of approximately the upper 1-millimeter of skin. The basic concept of producing well-controlled arrays of thermal injury is therefore limited with fractional photothermolysis, to superficial aspects of photoaging. Aging, which also causes laxity of the skin, and photoaging involve deeper layers of the dermis. Solar elastosis can extend throughout the dermis, to approximately 3 mm deep or more. Laxity and loss of elasticity due to aging are bulk problems of the dermis.

A fundamental requirement for producing arrays of small thermal injury zones using a source of radiant energy that propagates and is absorbed within tissue, is that the source of radiant energy be capable of being adequately delivered to the tissue depth for which the array is desired. Near the skin surface, light can be used, as in fractional photothermolysis. However, light that propagates more than about 1 mm through skin has been multiplied scattered, and can no longer be focused or delivered.

## SUMMARY

A method and system for ultrasound treatment of photoaged tissue are provided. An exemplary method and system are configured for first, ultrasound imaging of the region of interest for localization of the treatment area, second, delivery of ultrasound energy at a depth and pattern to achieve the desired therapeutic effects, and third to monitor the treatment area during and after therapy to assess the results and/or provide feedback. The exemplary treatment method and system can be configured for producing arrays of sub-millimeter and larger zones of thermal ablation to treat the epidermal, superficial dermal, mid-dermal and deep dermal components of photoaged tissue.

In accordance with an exemplary embodiment, the treatment method and system use focused, unfocused, and/or defocused ultrasound for treatment of epidermal, superficial dermal, dermal, mid-dermal, and/or deep dermal components of photoaged tissue by adjusting the strength, depth, and/or type of focusing, energy levels and timing cadence. For example, focused ultrasound can be used to create precise arrays of microscopic thermal damage much deeper into the skin or even into subcutaneous structures. Detection of changes in the reflection of ultrasound can be used for feedback control to detect a desired effect on the tissue and used to control the exposure intensity, time, and/or position.

In accordance with an exemplary embodiment, an exemplary treatment system comprises an imaging/therapy probe, a control system and display system. The imaging/therapy probe can comprise various probe and/or transducer configurations. For example, the probe can be configured for a combined dual-mode imaging/therapy transducer, coupled or co-housed imaging/therapy transducers, a separate therapy probe and imaging probe, or a single therapy probe. The control system and display system can also comprise various configurations for controlling probe and system functionality, including for example a microprocessor with software and a plurality of input/output and communication devices, a system for controlling electronic and/or mechanical scanning and/or multiplexing of transducers, a system

for power delivery, systems for monitoring, systems for sensing the spatial position of the probe and/or temporal parameters of the transducers, and systems for handling user input and recording treatment input and results, among others.

### BRIEF DESCRIPTION OF THE DRAWINGS

The subject matter of the invention is particularly pointed out in the concluding portion of the specification. The invention, however, both as to organization and method of operation, may best be understood by reference to the following description taken in conjunction with the accompanying drawing figures, in which like parts may be referred to by like numerals:

FIG. 1 illustrates a block diagram of a treatment system in accordance with an exemplary embodiment of the present invention;

FIGS. 2A-2D illustrates a schematic diagram of an ultrasound treatment system including therapy, imaging and/or monitoring and treating photoaged tissue in accordance with various exemplary embodiments of the present invention;

FIGS. 3A and 3B illustrate block diagrams of an exemplary control system in accordance with exemplary embodiments of the present invention;

FIGS. 4A and 4B illustrate block diagrams of an exemplary probe system in accordance with exemplary embodiments of the present invention;

FIG. 5 illustrates a cross-sectional diagram of an exemplary transducer in accordance with an exemplary embodiment of the present invention;

FIGS. 6A and 6B illustrate cross-sectional diagrams of an exemplary transducer in accordance with exemplary embodiments of the present invention;

FIG. 7 illustrates exemplary transducer configurations for ultrasound treatment in accordance with various exemplary embodiments of the present invention;

FIGS. 8A and 8B illustrate cross-sectional diagrams of an exemplary transducer in accordance with another exemplary embodiment of the present invention;

FIG. 9 illustrates an exemplary transducer configured as a two-dimensional, array for ultrasound treatment in accordance with an exemplary embodiment of the present invention;

FIGS. 10A-10F illustrate cross-sectional diagrams of exemplary transducers in accordance with other exemplary embodiments of the present invention;

FIG. 11 illustrates a schematic diagram of an acoustic coupling and cooling system in accordance with an exemplary embodiment of the present invention;

FIG. 12 illustrates a block diagram of an ultrasound treatment system combined with additional subsystems and methods of treatment monitoring and/or treatment imaging as well as a secondary treatment subsystem in accordance with an exemplary embodiment of the present invention; and

FIG. 13 illustrates a schematic diagram with imaging, therapy, or monitoring being provided with one or more active or passive oral inserts in accordance with an exemplary embodiment of the present invention.

### DETAILED DESCRIPTION

The present invention may be described herein in terms of various functional components and processing steps. It should be appreciated that such components and steps may be realized by any number of hardware components configured to perform the specified functions. For example, the

present invention may employ various medical treatment devices, visual imaging and display devices, input terminals and the like, which may carry out a variety of functions under the control of one or more control systems or other control devices. In addition, the present invention may be practiced in any number of medical contexts and that the exemplary embodiments relating to a method and system for treating photoaged tissue as described herein are merely indicative of exemplary applications for the invention. For example, the principles, features and methods discussed may be applied to any medical application. Further, various aspects of the present invention may be suitably applied to other applications.

In accordance with various aspects of the present invention, a method and system for treating photoaged tissue are provided. For example, in accordance with an exemplary embodiment, with reference to FIG. 1, an exemplary treatment system 100 configured to treat a region of interest (ROI) 106 comprises a control system 102, an imaging/therapy probe with acoustic coupling 104, and a display system 108. Control system 102 and display 108 can comprise various configurations for controlling functionality of probe 104 and system 100, including for example a micro-processor with software and a plurality of input/output and communication devices, a system for controlling electronic and/or mechanical scanning and/or multiplexing of transducers, a system for power delivery, systems for monitoring, systems for sensing the spatial position of the probe and/or temporal parameters of the transducers, and/or systems for handling user input and recording treatment input and results, among others. Imaging/therapy probe 104 can comprise various probe and/or transducer configurations. For example, probe 104 can be configured for a combined dual-mode imaging/therapy transducer, coupled or co-housed imaging/therapy transducers, a separate therapy probe and separate imaging probe, or a single therapy probe. In accordance with exemplary embodiments, imaging transducers may operate at frequencies from approximately 2 to 75 MHz or more, while therapy energy can be delivered at frequencies from approximately 2 to 50 MHz, with 2 MHz to 25 MHz being typical.

For the treatment of photoaged tissue, it is desirable to be able to produce well controlled arrays of microscopic zones of thermal injury not only near the surface of skin, but in the mid-dermis, and/or in the deep dermis. Thermal ablation of dermis at temperatures greater than about 60° C., capable of producing denaturation of tissue, is also desirable in such arrays of thermal lesions. Shrinkage of dermis due to thermal action results from tightening of the skin.

In contrast to optical or RF approaches, ultrasound energy propagates as a wave with relatively little scattering, over depths up to many centimeters in tissue depending on the ultrasound frequency. The focal spot size achievable with any propagating wave energy, depends on wavelength. Ultrasound wavelength is equal to the acoustic velocity divided by the ultrasound frequency. Attenuation (absorption, mainly) of ultrasound by tissue also depends on frequency.

In accordance with an exemplary embodiment, the use of focused, unfocused, or defocused ultrasound for treatment of epidermal, superficial dermal, dermal, middermal, and deep dermal components of photoaged tissue through adjustment of the strength, depth, and type of focusing, energy levels and timing cadence. For example, focused ultrasound can be used to create precise arrays of microscopic thermal ablation zones which have several advantages over fractional photothermolysis (FP). At high frequency and with superficial

focusing or diffraction pattern, ultrasound ablation can mimic FP but utilize a simpler ablation device. Unlike fractional photothermolysis, ultrasound can produce an array of ablation zones much deeper into the skin or even into subcutaneous structures. Detection of changes in the reflection of ultrasound can be used for feedback control to detect a desired effect on the tissue and used to control the exposure intensity, time, and/or position.

To further illustrate the use of ultrasound for the treatment of photoaged tissue, with reference to FIG. 2A, an exemplary method and system are configured for initially imaging a region **222** of a region of interest **206** and displaying that region **224** during the localization of the treatment area and surrounding structures. After localization, delivery of ultrasound energy **220** at a depth, distribution, timing, and energy level to achieve the desired therapeutic effect of thermal ablation to treat an epidermis layer **212**, superficial dermis layer **214**, mid-dermis layer **216**, and/or deep dermis layer **218** can be provided. Before, during, and after therapy, i.e., before, during, and after the delivery of ultrasound energy **220**, exemplary method and system **200** can suitably monitor the treatment area and surrounding structures to plan and assess the results and/or provide feedback to control system **202** and/or a system user.

While an imaging function may be configured within control system **202** to facilitate imaging a region of interest, in accordance with another exemplary embodiment, an exemplary treatment system **200** may also be configured for therapy only or therapy and monitoring, without imaging functions. In such a case prior known depth of the region of interest, approximately 0 to 5 mm or less, is employed to achieve treatment zones in photoaged skin.

Probe **204** and/or transducers within can be mechanically and/or electronically scanned in a direction **226** to place treatment zones **260** over an extended area, such as a line to generate a matrix of closely spaced treatment spots. Treatment depth **220** can be adjusted between a range of approximately 0 to 5 mm, or otherwise until the depth of the deep dermis. Treatment may be confined to a fixed depth or a few discrete depths, or can be adjustment limited to a fine range, e.g. from approximately between 0 to 5 mm or the greatest depth of the deep dermis, or can be dynamically adjusted during treatment, to the treat region of interest **206** that lies above subcutaneous fat region **250**.

In accordance with another exemplary embodiment of the present invention, with reference to FIG. 2B, a treated zone **260** may extend throughout regions of the dermis, and may even extend to the epidermis, **262**. In addition, as a treated zone increases in depth its cross section may increase from small size **264** (sub millimeter) in a shallow region near or at the epidermis, to medium size **266** (sub millimeter to millimeter sized) in a middle zone near or at the mid dermis, to large size **268** (millimeter sized) in deep zones near or at the deep dermis. Furthermore a. single treated zone can have a shape expanding in cross section with depth, and/or be composed of the fusion of several smaller treatment zones. Spacing of treatment zones can be on the order of the treatment zone size. The ultrasound beam can be spatially and/or temporally controlled by changing the position of the transducer, its frequency, treatment depth, drive amplitude, and timing via the control system. For example, the ultrasound beam can be controlled as set forth in U.S. patent application Ser. No. 11/163,148, filed Oct. 6, 2005, and entitled METHOD AND SYSTEM FOR CONTROLLED THERMAL INJURY OF HUMAN SUPERFICIAL TISSUE, and hereby incorporated by reference.

In accordance with another exemplary embodiment of the present invention, with reference to FIG. 2C, an exemplary treatment method and system **200** may be configured to monitor the temperature profile or other tissue parameters of region of interest **206**, such as attenuation or speed of sound of the treatment region and suitably adjust the spatial and/or temporal characteristics and energy levels of the ultrasound therapy transducer. The results of such monitoring techniques may be indicated on display **208**, such as through display of one-, two-, or three-dimensional images of monitoring results **270**, or may comprise an indicator **272**, such as a success, fail and/or completed/done type of indication, or combinations thereof. Additional treatment monitoring methods may be based on one or more of temperature, video, profilometry, strain imaging and/or gauges or any other suitable sensing method.

In accordance with another exemplary embodiment, with reference to FIG. 20, an expanded region of interest **280** can suitably include a combination of tissues, such as subcutaneous fat/adipose tissue **250**. A combination of such tissues includes at least one of epidermis **212**, superficial dermis **214**, mid dermis **216**, or deep dermis **218**, in combination with at least one of muscle tissue, adipose tissue, or other tissues useful for treatment. For example, treatment **260** of superficial dermis may be performed in combination with treatment **220** of subcutaneous fat **250** by suitable adjustment of the spatial and temporal parameters of transducers in probe **204**.

An exemplary control system **202** and display system **208** may be configured in various manners for controlling probe and system functionality for providing the various exemplary treatment methods illustrated above. For example, with reference to FIGS. 3A and 3B, in accordance with exemplary embodiments, an exemplary control system **300** can be configured for coordination and control of the entire therapeutic treatment process for producing arrays of sub-millimeter and larger zones of thermal ablation to treat the epidermal, superficial dermal, mid-dermal and deep dermal components of photoaged tissue. For example, control system **300** can suitably comprise power source components **302**, sensing and monitoring components **304**, cooling and coupling controls **306**, and/or processing and control logic components **308**. Control system **300** can be configured and optimized in a variety of ways with more or less subsystems and components to implement the therapeutic system for controlled thermal injury of photoaged tissue, and the embodiments in FIGS. 3A and 3B are merely for illustration purposes.

For example, for power sourcing components **302**, control system **300** can comprise one or more direct current (DC) power supplies **303** configured to provide electrical energy for entire control system **300**, including power required by a transducer electronic amplifier/driver **312**. A DC current sense device **305** can also be provided to confirm the level of power going into amplifiers/drivers **312** for safety and monitoring purposes.

Amplifiers/drivers **312** can comprise multi-channel or single channel power amplifiers and/or drivers. In accordance with an exemplary embodiment for transducer array configurations, amplifiers/drivers **312** can also be configured with a beamformer to facilitate array focusing. An exemplary beamformer can be electrically excited by an oscillator/digitally controlled waveform synthesizer **310** with related switching logic.

The power sourcing components can also include various filtering configurations **314**. For example, switchable harmonic filters and/or matching may be used at the output of

amplifier/driver **312** to increase the drive efficiency and effectiveness. Power detection components **316** may also be included to confirm appropriate operation and calibration. For example, electric power and other energy detection components **316** may be used to monitor the amount of power going to an exemplary probe system.

Various sensing and monitoring components **304** may also be suitably implemented within control system **300**. For example, in accordance with an exemplary embodiment, monitoring, sensing and interface control components **324** may be configured to operate with various motion detection systems implemented within transducer probe **204** to receive and process information such as acoustic or other spatial and temporal information from a region of interest. Sensing and monitoring components can also include various controls, interfacing and switches **309** and/or power detectors **316**. Such sensing and monitoring components **304** can facilitate open-loop and/or closed-loop feedback systems within treatment system **200**.

Cooling/coupling control systems **306** may be provided to remove waste heat from an exemplary probe **204**, provide a controlled temperature at the superficial tissue interface and deeper into tissue, and/or provide acoustic coupling from transducer probe **204** to region-of-interest **206**. Such cooling/coupling control systems **306** can also be configured to operate in both open-loop and/or closed-loop feedback arrangements with various coupling and feedback components.

Processing and control logic components **308** can comprise various system processors and digital control logic **307**, such as one or more of microcontrollers, microprocessors, field-programmable gate arrays (FPGAs), computer boards, and associated components, including firmware and control software **326**, which interfaces to user controls and interfacing circuits as well as input/output circuits and systems for communications, displays, interfacing, storage, documentation, and other useful functions. System software and firmware **326** controls all initialization, timing, level setting, monitoring, safety monitoring, and all other system functions required to accomplish user-defined treatment objectives. Further, various control switches **308** can also be suitably configured to control operation.

An exemplary transducer probe **204** can also be configured in various manners and comprise a number of reusable and/or disposable components and parts in various embodiments to facilitate its operation. For example, transducer probe **204** can be configured within any type of transducer probe housing or arrangement for facilitating the coupling of transducer to a tissue interface, with such housing comprising various shapes, contours and configurations. Transducer probe **204** can comprise any type of matching, such as for example, electric matching, which may be electrically switchable; multiplexer circuits and/or aperture/element selection circuits; and/or probe identification devices, to certify probe handle, electric matching, transducer usage history and calibration, such as one or more serial EEPROM (memories). Transducer probe **204** may also comprise cables and connectors; motion mechanisms, motion sensors and encoders; thermal monitoring sensors; and/or user control and status related switches, and indicators such as LEDs. For example, a motion mechanism in probe **204** may be used to controllably create multiple lesions, or sensing of probe motion itself may be used to controllably create multiple lesions and/or stop creation of lesions, e.g. for safety reasons if probe **204** is suddenly jerked or is dropped. In addition, an external motion encoder arm may be used to hold the probe during use, whereby the spatial position and attitude of

probe **104** is sent to the control system to help controllably create lesions. Furthermore, other sensing functionality such as profilometers or other imaging modalities may be integrated into the probe in accordance with various exemplary embodiments.

With reference to FIGS. **4A** and **4B**, in accordance with an exemplary embodiment, a transducer probe **400** can comprise a control interface **402**, a transducer **404**, coupling components **406**, and monitoring/sensing components **408**, and/or motion mechanism **410**. However, transducer probe **400** can be configured and optimized in a variety of ways with more or less parts and components to provide ultrasound energy for controlled thermal injury of photoaged tissue, and the embodiments in FIGS. **4A** and **4B** are merely for illustration purposes.

Control interface **402** is configured for interfacing with control system **300** to facilitate control of transducer probe **400**. Control interface components **402** can comprise multiplexer/aperture select **424**, switchable electric matching networks **426**, serial EEPROMs and/or other processing components and matching and probe usage information **430** and interface connectors **432**.

Coupling components **406** can comprise various devices to facilitate coupling of transducer probe **400** to a region of interest. For example, coupling components **406** can comprise cooling and acoustic coupling system **420** configured for acoustic coupling of ultrasound energy and signals. Acoustic cooling/coupling system **420** with possible connections such as manifolds may be utilized to couple sound into the region-of-interest, control temperature at the interface and deeper into tissue, provide liquid-filled lens focusing, and/or to remove transducer waste heat. Coupling system **420** may facilitate such coupling through use of various coupling mediums, including air and other gases, water and other fluids, gels, solids, and/or any combination thereof, or any other medium that allows for signals to be transmitted between transducer active elements **412** and a region of interest. In addition to providing a coupling function, in accordance with an exemplary embodiment, coupling system **420** can also be configured for providing temperature control during the treatment application. For example, coupling system **420** can be configured for controlled cooling of an interface surface or deeper region between transducer probe **400** and a region of interest and beyond by suitably controlling the temperature of the coupling medium. The suitable temperature for such coupling medium can be achieved in various manners, and utilize various feedback systems, such as thermocouples, thermistors or any other device or system configured for temperature measurement of a coupling medium. Such controlled cooling can be configured to further facilitate spatial and/or thermal energy delivery control of transducer probe **400**.

In accordance with an exemplary embodiment, with additional reference to FIG. **11**, acoustic coupling and cooling **1140** can be provided to acoustically couple energy and imaging signals from transducer probe **1104** to and from the region of interest **1102**, to provide thermal control at the probe to region-of-interest interface **1110** and deeper into tissue, and to remove potential waste heat from the transducer probe at region **1144**. Temperature monitoring can be provided at the coupling interface via a thermal sensor **1146** to provide a mechanism of temperature measurement **1148** and control via control system **1106** and a thermal control system **1142**. Thermal control may consist of passive cooling such as via heat sinks or natural conduction and convection or via active cooling such as with peltier thermoelectric coolers, refrigerants, or fluid-based systems

comprised of pump, fluid reservoir, bubble detection, flow sensor, flow channels/tubing 1144 and thermal control 1142.

With continued reference to FIG. 4, monitoring and sensing components 408 can comprise various motion and/or position sensors 416, temperature monitoring sensors 418, user control and feedback switches 414 and other like components for facilitating control by control system 300, e.g., to facilitate spatial and/or temporal control through open-loop and closed-loop feedback arrangements that monitor various spatial and temporal characteristics.

Motion mechanism 410 can comprise manual operation, mechanical arrangements, or some combination thereof. For example, a motion mechanism 422 can be suitably controlled by control system 300, such as through the use of accelerometers, encoders or other position/orientation devices 416 to determine and enable movement and positions of transducer probe 400. Linear, rotational or variable movement can be facilitated, e.g., those depending on the treatment application and tissue contour surface.

Transducer 404 can comprise one or more transducers configured for treating of SMAS layers and targeted regions. Transducer 404 can also comprise one or more transduction elements and/or lenses 412. The transduction elements can comprise a piezoelectrically active material, such as lead zirconate titanate (PZT), or any other piezoelectrically active material, such as a piezoelectric ceramic, crystal, plastic, and/or composite materials, as well as lithium niobate, lead titanate, barium titanate, and/or lead metaniobate. In addition to, or instead of, a piezoelectrically active material, transducer 404 can comprise any other materials configured for generating radiation and/or acoustical energy. Transducer 404 can also comprise one or more matching layers configured along with the transduction element such as coupled to the piezoelectrically active material. Acoustic matching layers and/or damping may be employed as necessary to achieve the desired electroacoustic response.

In accordance with an exemplary embodiment, the thickness of the transduction element of transducer 404 can be configured to be uniform. That is, a transduction element 412 can be configured to have a thickness that is substantially the same throughout. In accordance with another exemplary embodiment, the thickness of a transduction element 412 can also be configured to be variable. For example, transduction element(s) 412 of transducer 404 can be configured to have a first thickness selected to provide a center operating frequency of approximately 2 kHz to 75 MHz, such as for imaging applications. Transduction element 412 can also be configured with a second thickness selected to provide a center operating frequency of approximately 2 to 50 MHz, and typically between 2 MHz and 25 MHz for therapy application. Transducer 404 can be configured as a single broadband transducer excited with at least two or more frequencies to provide an adequate output for generating a desired response. Transducer 404 can also be configured as two or more individual transducers, wherein each transducer comprises one or more transduction element. The thickness of the transduction elements can be configured to provide center-operating frequencies in a desired treatment range.

Transducer 404 may be composed of one or more individual transducers in any combination of focused, planar, or unfocused single-element, multi-element, or array transducers, including 1-D, 2-D, and annular arrays; linear, curvilinear, sector, or spherical arrays; spherically, cylindrically, and/or electronically focused, defocused, and/or lensed sources. For example, with reference to an exemplary embodiment depicted in FIG. 5, transducer 500 can be

configured as an acoustic array 502 to facilitate phase focusing. That is, transducer 500 can be configured as an array of electronic apertures that may be operated by a variety of phases via variable electronic time delays. By the term "operated," the electronic apertures of transducer 500 may be manipulated, driven, used, and/or configured to produce and/or deliver an energy beam corresponding to the phase variation caused by the electronic time delay. For example, these phase variations can be used to deliver defocused beams 508, planar beams 504, and/or focused beams 506, each of which may be used in combination to achieve different physiological effects in a region of interest 510. Transducer 500 may additionally comprise any software and/or other hardware for generating, producing and/or driving a phased aperture array with one or more electronic time delays.

Transducer 500 can also be configured to provide focused treatment to one or more regions of interest using various frequencies. In order to provide focused treatment, transducer 500 can be configured with one or more variable depth devices to facilitate treatment. For example, transducer 500 may be configured with variable depth devices disclosed in U.S. patent application Ser. No. 10/944,500, entitled "System and Method for Variable Depth Ultrasound", filed on Sep. 16, 2004, having at least one common inventor and a common Assignee as the present application, and incorporated herein by reference. In addition, transducer 500 can also be configured to treat one or more additional ROI 510 through the enabling of sub-harmonics or pulseecho imaging, as disclosed in U.S. patent application Ser. No. 10/944,499, entitled "Method and System for Ultrasound Treatment with a Multi-directional Transducer," filed on Sep. 16, 2004, having at least one common inventor and a common Assignee as the present application, and also incorporated herein by reference.

Moreover, any variety of mechanical lenses or variable focus lenses, e.g. liquid-filled lenses, may also be used to focus and or defocus the sound field. For example, with reference to exemplary embodiments depicted in FIGS. 6A and 6B, transducer 600 may also be configured with an electronic focusing array 604 in combination with one or more transduction elements 606 to facilitate increased flexibility in treating ROI 610. Array 604 may be configured in a manner similar to transducer 502. That is, array 604 can be configured as an array of electronic apertures that may be operated by a variety of phases via variable electronic time delays, for example, T<sub>1</sub>, T<sub>2</sub> . . . T<sub>j</sub>. By the term "operated," the electronic apertures of array 604 may be manipulated, driven, used, and/or configured to produce and/or deliver energy in a manner corresponding to the phase variation caused by the electronic time delay. For example, these phase variations can be used to deliver defocused beams, planar beams, and/or focused beams, each of which may be used in combination to achieve different physiological effects in ROI 610.

Transduction elements 606 may be configured to be concave, convex, and/or planar. For example, in an exemplary embodiment depicted in FIG. 6A, transduction elements 606 are configured to be concave in order to provide focused energy for treatment of ROI 610. Additional embodiments are disclosed in U.S. patent application Ser. No. 10/944,500, entitled "Variable Depth Transducer System and Method", and again incorporated herein by reference.

In another exemplary embodiment, depicted in FIG. 6B, transduction elements 606 can be configured to be substantially flat in order to provide substantially uniform energy to

11

ROI **610**. While FIGS. **6A** and **6B** depict exemplary embodiments with transduction elements **604** configured as concave and substantially flat, respectively, transduction elements **604** can be configured to be concave, convex, and/or substantially flat. In addition, transduction elements **604** can be configured to be any combination of concave, convex, and/or substantially flat structures. For example, a first transduction element can be configured to be concave, while a second transduction element can be configured to be substantially flat.

With reference to FIGS. **8A** and **8B**, transducer **404** can be configured as single-element arrays, wherein a single-element **802**, e.g., a transduction element of various structures and materials, can be configured with a plurality of masks **804**, such masks comprising ceramic, metal or any other material or structure for masking or altering energy distribution from element **802**, creating an array of energy distributions **808**. Masks **804** can be coupled directly to element **802** or separated by a standoff **806**, such as any suitably solid or liquid material.

An exemplary transducer **404** can also be configured as an annular array to provide planar, focused and/or defocused acoustical energy. For example, with reference to FIGS. **10A** and **10B**, in accordance with an exemplary embodiment, an annular array **1000** can comprise a plurality of rings **1012**, **1014**, **1016** to N. Rings **1012**, **1014**, **1016** to N can be mechanically and electrically isolated into a set of individual elements, and can create planar, focused, or defocused waves. For example, such waves can be centered on-axis, such as by methods of adjusting corresponding transmit and/or receive delays,  $T_1, T_2, T_3 \dots T_N$ . An electronic focus can be suitably moved along various depth positions, and can enable variable strength or beam tightness, while an electronic defocus can have varying amounts of defocusing. In accordance with an exemplary embodiment, a lens and/or convex or concave shaped annular array **1000** can also be provided to aid focusing or defocusing such that any time differential delays can be reduced. Movement of annular array **800** in one, two or three-dimensions, or along any path, such as through use of probes and/or any conventional robotic arm mechanisms, may be implemented to scan and/or treat a volume or any corresponding space within a region of interest.

Transducer **404** can also be configured in other annular or non-array configurations for imaging/therapy functions. For example, with reference to FIGS. **10C-10F**, a transducer can comprise an imaging element **1012** configured with therapy element(s) **1014**. Elements **1012** and **1014** can comprise a single-transduction element, e.g., a combined imaging/transducer element, or separate elements, can be electrically isolated **1022** within the same transduction element or between separate imaging and therapy elements, and/or can comprise standoff **1024** or other matching layers, or any combination thereof. For example, with particular reference to FIG. **10F**, a transducer can comprise an imaging element **1012** having a surface **1028** configured for focusing, defocusing or planar energy distribution, with therapy elements **1014** including a stepped-configuration lens configured for focusing, defocusing, or planar energy distribution.

In accordance with various exemplary embodiments of the present invention, transducer **404** may be configured to provide one, two and/or three-dimensional treatment applications for focusing acoustic energy to one or more regions of interest. For example, as discussed above, transducer **404** can be suitably diced to form a one-dimensional array, e.g., transducer **602** comprising a single array of sub-transduction elements.

12

In accordance with another exemplary embodiment, transducer **404** may be suitably diced in two-dimensions to form a two-dimensional array. For example, with reference to FIG. **9**, an exemplary two-dimensional array **900** can be suitably diced into a plurality of two-dimensional portions **902**. Two-dimensional portions **902** can be suitably configured to focus on the treatment region at a certain depth, and thus provide respective slices **904**, **907** of the treatment region. As a result, the two-dimensional array **900** can provide a two-dimensional slicing of the image plane of a treatment region, thus providing two-dimensional treatment.

In accordance with another exemplary embodiment, transducer **404** may be suitably configured to provide three-dimensional treatment. For example, to provide three-dimensional treatment of a region of interest, with reference again to FIG. **1**, a three-dimensional system can comprise a transducer within probe **104** configured with an adaptive algorithm, such as, for example, one utilizing three-dimensional graphic software, contained in a control system, such as control system **102**. The adaptive algorithm is suitably configured to receive two-dimensional imaging, temperature and/or treatment or other tissue parameter information relating to the region of interest, process the received information, and then provide corresponding three-dimensional imaging, temperature and/or treatment information.

In accordance with an exemplary embodiment, with reference again to FIG. **9**, an exemplary three-dimensional system can comprise a two-dimensional array **900** configured with an adaptive algorithm to suitably receive **904** slices from different image planes of the treatment region, process the received information, and then provide volumetric information **906**, e.g., three-dimensional imaging, temperature and/or treatment information. Moreover, after processing the received information with the adaptive algorithm, the two-dimensional array **900** may suitably provide therapeutic heating to the volumetric region **906** as desired.

In accordance with other exemplary embodiments, rather than utilizing an adaptive algorithm, such as three-dimensional software, to provide three-dimensional imaging and/or temperature information, an exemplary three-dimensional system can comprise a single transducer **404** configured within a probe arrangement to operate from various rotational and/or translational positions relative to a target region.

To further illustrate the various structures for transducer **404**, with reference to FIG. **7**, ultrasound therapy transducer **700** can be configured for a single focus, an array of foci, a locus of foci, a line focus, and/or diffraction patterns. Transducer **700** can also comprise single elements, multiple elements, annular arrays, one-, two-, or three-dimensional arrays, broadband transducers, and/or combinations thereof, with or without lenses, acoustic components, and mechanical and/or electronic focusing. Transducers configured as spherically focused single elements **702**, annular arrays **704**, annular arrays with damped regions **706**, line focused single elements **708**, 1-D linear arrays **710**, 1-D curvilinear arrays in concave or convex form, with or without elevation focusing, 2-D arrays, and 3-D spatial arrangements of transducers may be used to perform therapy and/or imaging and acoustic monitoring functions. For any transducer configuration, focusing and/or defocusing may be in one plane or two planes via mechanical focus **720**, convex lens **722**, concave lens **724**, compound or multiple lenses **726**, planar form **728**, or stepped form, such as illustrated in FIG. **10F**. Any transducer or combination of transducers may be utilized for treatment. For example, an annular transducer may be used with an outer portion dedicated to therapy and the inner disk

13

dedicated to broadband imaging wherein such imaging transducer and therapy transducer have different acoustic lenses and design, such as illustrated in FIG. 1 OC-1 OF.

Moreover, such transduction elements 700 may comprise a piezoelectrically active material, such as lead zirconate titanate (PZT), or any other piezoelectrically active material, such as a piezoelectric ceramic, crystal, plastic, and/or composite materials, as well as lithium niobate, lead titanate, barium titanate, and/or lead metaniobate. Transduction elements 700 may also comprise one or more matching layers configured along with the piezoelectrically active material. In addition to or instead of piezoelectrically active material, transduction elements 700 can comprise any other materials configured for generating radiation and/or acoustical energy. A means of transferring energy to and from the transducer to the region of interest is provided.

In accordance with another exemplary embodiment, with reference to FIG. 12, an exemplary treatment system 200 can be configured with and/or combined with various auxiliary systems to provide additional functions. For example, an exemplary treatment system 1200 for treating a region of interest 1202 can comprise a control system 1206, a probe 1204, and a display 1208. Treatment system 1200 further comprises an auxiliary imaging modality 1272 and/or auxiliary monitoring modality 1274 may be based upon at least one of photography and other visual optical methods, magnetic resonance imaging (MRI), computed tomography (CT), optical coherence tomography (OCT), electromagnetic, microwave, or radio frequency (RF) methods, positron emission tomography (PET), infrared, ultrasound, acoustic, or any other suitable method of visualization, localization, or monitoring of epidermal, superficial dermal, mid-dermal and deep dermal components within the region-of-interest 1202, including imaging/monitoring enhancements. Such imaging/monitoring enhancement for ultrasound imaging via probe 1204 and control system 1206 could comprise M-mode, persistence, filtering, color, Doppler, and harmonic imaging among others; furthermore an ultrasound treatment system 1270, as a primary source of treatment, may be combined with a secondary source of treatment 1276, including radio frequency (RF), intense pulsed light (IPL), laser, infrared laser, microwave, or any other suitable energy source.

In accordance with another exemplary embodiment, with reference to FIG. 13, treatment composed of imaging, monitoring, and/or therapy to a region of interest 1302 and/or 1308 may be aided, augmented, and/or delivered with passive or active devices 1304 and/or 1306 within the oral and/or nasal cavity, respectively. For example, if passive or active device 1304 and/or 1306 are second transducers or acoustic reflectors acoustically coupled to the mucous membranes it is possible to obtain through transmission, tomographic, or round-trip acoustic waves which are useful for treatment monitoring, such as in measuring acoustic speed of sound and attenuation, which are temperature dependent; furthermore such transducers could be used to treat and/or image. In addition an active, passive, or active/passive object 1304 and/or 1306 may be used to flatten the skin, and/or may be used as an imaging grid, marker, or beacon, to aid determination of position. A passive or active device 1304 and/or 1306 may also be used to aid cooling or temperature control. Natural air in the oral cavity and/or nasal cavity may also be used as passive device 1304 and/or 1306 whereby it may be utilized to as an acoustic reflector to aid thickness measurement and monitoring function.

The present invention has been described above with reference to various exemplary embodiments. However,

14

those skilled in the art will recognize that changes and modifications may be made to the exemplary embodiments without departing from the scope of the present invention. For example, the various operational steps, as well as the components for carrying out the operational steps, may be implemented in alternate ways depending upon the particular application or in consideration of any number of cost functions associated with the operation of the system, e.g., various of the steps may be deleted, modified, or combined with other steps. These and other changes or modifications are intended to be included within the scope of the present invention, as set forth in the following claims.

What is claimed is:

1. An ultrasound system for treatment of skin laxity, the system comprising:

an ultrasound probe comprising a housing, wherein the housing comprises a motion mechanism and an ultrasound transducer,

wherein the ultrasound transducer comprises a therapy component and an imaging component,

wherein the therapy component consists of:

a single active spherically-focused ultrasound therapy element,

wherein the ultrasound therapy element is configured to provide a single mechanical focus,

wherein the single mechanical focus is configured to provide ultrasound therapy energy in the form of a single thermal focus in a tissue at a depth below a skin surface,

wherein the depth is a single, fixed depth in a range of up to 5 mm below the skin surface to treat the tissue, wherein the tissue comprises a combination of any of the group consisting of: an epidermal tissue, a superficial dermal tissue, a mid-dermal tissue, a deep dermal tissue, a muscle tissue, and an adipose tissue,

wherein the single thermal focus is formed without electronic focusing and without a lens,

wherein the imaging component comprises an ultrasound imaging element,

wherein the ultrasound imaging element is configured for imaging a region of interest under the skin surface, wherein the region of interest comprises the tissue,

wherein a portion of the ultrasound probe is configured for acoustic coupling to a skin surface;

a control system connected to the motion mechanism and the ultrasound therapy element;

a display configured to display an image of the region of interest;

an input device connected to the control system; and

a power supply connected to the control system;

wherein the ultrasound imaging element is connected to the display and the control system,

wherein the ultrasound therapy element is configured for delivery of energy at a temperature sufficient to shrink at least a portion of the tissue at the depth under the skin surface,

wherein the ultrasound therapy element is connected to the motion mechanism,

wherein the motion mechanism moves the ultrasound therapy element to form a plurality of thermal lesions at the depth for shrinking at least a portion of the tissue for reducing the appearance of skin laxity.

2. The system of claim 1, wherein the imaging element is configured for imaging at a frequency range of 2 MHz to 75 MHz,

wherein the imaging component and the therapy component are co-housed within the ultrasound probe,

## 15

wherein the ultrasound therapy element is configured to increase the temperature of the tissue in the region of interest to greater than 60° C.

3. The system of claim 1, further comprising a monitoring system,

wherein the monitoring system is configured to monitor a treatment parameter, wherein the treatment parameter measured comprises a temperature of the tissue below the skin surface,

wherein the housing further comprises a temperature monitoring sensor,

wherein the therapy element is a single element that delivers ultrasound energy at a frequency of between 2 MHz to 25 MHz.

4. The system of claim 1, wherein the housing contains a temperature monitoring sensor,

wherein the control system comprises a processor, software, and a communication device,

wherein the ultrasound probe is connected to the control system via a cable,

wherein the processor relays data from the temperature monitoring sensor via the communication device.

5. The system of claim 1,

wherein the motion mechanism comprises an encoder and the ultrasound energy is configured to deliver an energy level for causing at least one of shrinking collagen and denaturing the tissue in the region of interest under a wrinkle,

wherein the therapy element delivers ultrasound energy at a frequency of between 2 MHz to 25 MHz.

6. The system of claim 1, wherein the control system comprises a spatial control and a temporal control,

wherein the spatial control and the temporal control are configured for controlling the delivery of energy at a temperature sufficient to cause denaturation of at least the portion of the tissue at the depth under the skin surface,

wherein the spatial control and the temporal control are configured for controlling the delivery of energy at a frequency of between 2 MHz to 25 MHz.

7. An ultrasound system for treatment of skin laxity, the system comprising:

an ultrasound probe configured for delivery of an ultrasound energy at a temperature sufficient to heat at least a portion of a tissue at a depth under a skin surface,

wherein the tissue comprises a combination of any of the group consisting of: an epidermal tissue, a superficial dermal tissue, a mid-dermal tissue, a deep dermal tissue, a muscle tissue, and an adipose tissue; and a control system;

wherein the ultrasound probe comprises a housing, wherein the housing comprises a motion mechanism and an ultrasound transducer,

wherein the ultrasound transducer comprises a therapy component and an imaging component,

wherein the therapy component consists of:

a single active ultrasound therapy element, wherein the single active ultrasound therapy element is configured to provide a single, spherically-focused mechanical focus,

wherein the single, spherically-focused mechanical focus is configured to provide ultrasound therapy energy in the form of a single thermal focus in the tissue at a depth below a skin surface,

wherein the single thermal focus is formed without electronic focusing and without a lens,

## 16

wherein the imaging component comprises an ultrasound imaging element,

wherein the ultrasound therapy element is in communication with the control system,

wherein the motion mechanism is in communication with the control system,

wherein the ultrasound therapy element is configured for delivery of the ultrasound energy at the temperature sufficient to heat the at least a portion of the tissue at the depth under the skin surface,

wherein the ultrasound therapy element is connected to a portion of the motion mechanism,

wherein the motion mechanism moves the ultrasound therapy element to form a plurality of thermal lesions at the depth for reducing the appearance of skin laxity.

8. The system of claim 7,

wherein the ultrasound imaging element is configured for imaging a region of interest under the skin surface, wherein the region of interest comprises the tissue, wherein the skin surface comprises a wrinkle.

9. The system of claim 7, further comprising a monitoring system,

wherein the monitoring system is configured to monitor a treatment parameter, wherein the treatment parameter measured comprises a temperature of the tissue below the skin surface,

wherein the housing further comprises a temperature monitoring sensor,

wherein the ultrasound therapy element delivers ultrasound energy at a frequency of between 2 MHz to 75 MHz.

10. The system of claim 7, wherein the ultrasound probe is connected to the control system via a cable, and wherein the control system comprises:

a communication device;

a motion mechanism control;

a processor, software, an input device, and a power supply.

11. The system of claim 7,

wherein the ultrasound therapy element is a single element that delivers ultrasound energy at a frequency of between 2 MHz to 25 MHz,

wherein the ultrasound therapy element is configured to increase the temperature of the tissue in the region of interest to greater than 60° C.

12. An ultrasound system for treatment of skin laxity, the system comprising:

an ultrasound probe comprising a housing, wherein the housing comprises a motion mechanism and an ultrasound transducer,

wherein the ultrasound transducer comprises a therapy component and an imaging component,

wherein the therapy component consists of:

a single active spherically-focused ultrasound therapy element,

wherein the ultrasound therapy element is configured to provide a single mechanical focus,

wherein the single mechanical focus is configured to provide ultrasound therapy energy in the form of a single thermal focus in a tissue at a depth below a skin surface,

wherein the depth is up to 5 mm below the skin surface,

wherein the tissue comprises a combination of any of the group consisting of: an epidermal tissue, a superficial dermal tissue, a mid-dermal tissue, a deep dermal tissue, an adipose tissue, and a muscle tissue,



17

wherein the single thermal focus is formed without electronic focusing and without a lens,  
 wherein the imaging component comprises an ultrasound imaging element,  
 a control system comprising a processor and power supply; and  
 a display,  
 wherein the ultrasound imaging element is in communication with the display,  
 wherein the ultrasound imaging element is configured for imaging the tissue,  
 wherein the display is configured to display an image of the tissue,  
 wherein the ultrasound therapy element is in communication with the control system,  
 wherein the ultrasound therapy element is configured for delivery of energy at a temperature sufficient to denature at least a portion of the tissue in the region of interest at a depth under the skin surface,  
 wherein the ultrasound therapy element is connected to a portion of the motion mechanism,  
 wherein the motion mechanism is in communication with the control system,  
 wherein the motion mechanism moves the ultrasound therapy element to form a plurality of thermal lesions at the depth for reducing skin laxity.  
**13.** The system of claim 12,  
 wherein the motion mechanism comprises an encoder,  
 wherein the ultrasound probe is connected to the control system via a cable,  
 wherein the imaging component and the ultrasound therapy component are co-housed within the ultrasound probe,  
 wherein the skin surface comprises a wrinkle.  
**14.** The system of claim 12, further comprising an acoustic coupler between the ultrasound probe and the skin surface,  
 wherein the therapy element is a single element that delivers ultrasound energy at a frequency of between 2 MHz to 25 MHz,

18

wherein the housing further comprises a temperature monitoring sensor.

**15.** The system of claim 12,  
 wherein the ultrasound imaging element and the ultrasound therapy element are in a combined transducer,  
 wherein the ultrasound therapy element is configured to increase the temperature of the tissue in the region of interest to greater than 60° C.

**16.** The system of claim 12,  
 wherein the ultrasound imaging element is separate from, and co-housed with, the ultrasound therapy element in the probe.

**17.** The system of claim 12, further comprising a monitoring system,

wherein the monitoring system is configured to monitor a treatment parameter, wherein the treatment parameter measured comprises a temperature of the tissue below the skin surface,

wherein the housing further comprises a temperature monitoring sensor.

**18.** The system of claim 12,  
 wherein the motion mechanism is a linear motion mechanism for linear movement of the ultrasound therapy element to form a plurality of thermal lesions along a line at the depth in the region of interest.

**19.** The system of claim 12,  
 wherein the motion mechanism is configured for any one of the group consisting of linear, rotational, and variable movement of the ultrasound therapy element.

**20.** The system of claim 12,  
 wherein the motion mechanism comprises an encoder for monitoring a position of the ultrasound therapy element on the motion mechanism in a housing of the probe,  
 wherein the therapy element is a single element that delivers ultrasound energy at a frequency of between 2 MHz to 25 MHz,

wherein the ultrasound therapy element is configured to deliver the energy at the depth below the skin surface.

\* \* \* \* \*